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ABSTRACT 
 
DANIEL ARTHUR CAÑOS:  Choline/ Betaine Habitual Intake and Incident Coronary Heart 
Disease 
(Under the direction of Gerardo Heiss, MD, PhD) 
 
 Increased whole blood levels of total choline have previously been found to be 
associated with cardiovascular disease. We estimated the association between dietary choline 
and betaine intake and risk of incident CHD in the Women’s Health Initiative (WHI) 
Observational Study (n=93,676) and the WHI Dietary Modification trial data (n=48,835) 
collected over 8-12 years of follow-up.  Food consumption data, quantified from the WHI 
Food Frequency Questionnaire (FFQ) were converted into estimates of daily intake of 
choline and betaine. These FFQ estimates were compared to four-day food records (FDFR) 
estimates, and reliability was quantified through the comparison of FFQs administered at 
baseline and one year follow-up. Based on the intra-individual variability for all interrelated 
nutrients models, we estimated the associations between choline and betaine and incident 
CHD corrected for reliability. Median daily choline and betaine intakes were 264 (IQR: 
201−341) and 164 (IQR: 114−230).  Only 10% of the population (n=14,313) met the 
adequate intake of 425 mg/day. Median daily intakes of choline and betaine respectively 
were 268 mg and 166 mg in Whites, 242 mg and 164 mg in Blacks, 250 mg and 123 mg in 
Hispanic/Latinos; 233 mg and 150 mg in Asian or Pacific Islanders. A mixed model 
assessing the joint intra-individual variability for all interrelated nutrients yielded reliability 
coefficients of (betaine) 0.50; (choline) 0.59; (total energy intake) 0.55; (total folate) 0.30;
iv 
(B6) 0.60, (B12) 0.55; (methionine) 0.56. Correlations between FFQ and FDFR estimates 
were highest for natural folate (0.32); choline (0.30); methionine (0.27). Correlations were 
lowest for betaine (0.22); total folate (0.12); B6 (0.08); B12 (0.10). Hazard ratios (HRs) 
associated with a one standard deviation (SD) nutrient density adjusted choline intake (35.30 
mg/dy per kilocarlorie) were 1.26 [95% confidence interval (CI): 1.09,1.46] for Blacks and 
1.06 (95% CI: 1.01,1.11) for Whites. After reliability correction, HRs were further from the 
null in Blacks [1.42 (95% CI: 1.03,1.86)] and Whites [HR: 1.13 (95% CI: 1.02,1.23)].  
In conclusion, choline intake was postively associated with incident CHD in Whites 
and Blacks with a substantially greater effect estimate within Blacks.  Correction for 
reliability demonstrated that measurement error results in substantial attenuation of effect 
estimates.  
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 CHAPTER I  
BACKGROUND AND SIGNIFICANCE 
I.1 Choline 
 Choline (trimethyl-beta-hydroxyethylammonium), discovered by Strecker in 18621 
and first chemically synthesized in 1866,2 is a quaternary ammonium compound that is 
widely distributed in plants and animals.3  Choline is a dietary component necessary for 
normal function of all cells.4  Prolonged (weeks to months) ingestion of a diet deficient in 
choline, with adequate though limited methionine and folate content, has consequences that 
include hepatic5, renal6, pancreatic4, cognitive6, and growth disorders7 in most mammals.  
Dietary choline occurs in free and esterified forms (i.e. phosphocholine, 
glycerophosphocholine, phosphatidylcholine, and sphingomyelin)8, excellent sources of 
which include liver, eggs, soybeans, and wheat germ (See Table I.1).9  In the human diet, 
most choline is consumed in the form of lecithin.  Lecithin, a term often used 
interchangeably with phosphatidylcholine, is a phosphatidylcholine-rich fraction prepared 
during commercial purification of phospholipids.3  It is added to commercially prepared 
foods as an emulsifier, a stabilizer, a dispersing aid, and an incidental additive, such as a 
release agent for baked goods.10, 11  Zeisel 20068 states that free and esterified choline forms 
are very likely exchangeable, however there is some evidence that they may have different  
bioavailability12 since the lipid-soluble forms (e.g. sphingomyelin) bypass the liver when 
 2 
 
absorbed from the diet, while the water-soluble forms (choline, phosphocholine, and 
glycerophosphocholine) enter the portal circulation and are mostly absorbed by the liver. 
 
Table I.1  Foods with the highest choline and betaine content from the United States 
Department of Agriculture Database for the choline content of common foods9 
          
  Betaine  Total choline 
  mg/100g of food   mg/100g of food  
Beef Liver  6  418 
Chicken Liver  11  290 
Pork  1  103 
Bacon  3  125 
Eggs  1  251 
Shrimp  218  71 
Wheat Bran  1339  74 
Wheat Germ  1241  152 
Wheat Bread  201  27 
Pretzels  237  38 
Cooked Spinach  645  25 
Dried Soybeans  2  116 
mg = milligrams, g = grams. 
 
I.1.1 Dietary Choline Absorption  
Choline and phosphatidylcholine are absorbed in the small intestine.13  Specifically, 
unesterified choline is absorbed in the lumen of the upper small intestine, primarily in the 
jejunum, by transporter proteins in enterocytes.14-18  The absorption of phosphatidylcholine 
occurs in a process independent from that of choline.3  Briefly, phosphatidylcholine is 
absorbed by enterocytes through a mechanism involving hydrolysis to form 
lysophosphatidylcholine, after which phosphatidylcholine is reformed through reacylation in 
the enterocyte.14  There is little known about the mechanisms which mediate the absorption 
of the other choline compounds found in foods: phosphocholine, sphingomyelin, and 
glycerophosphocholine.12, 15  Generally speaking, it is known that water-soluble choline 
3 
compounds are absorbed through the portal circulation and are mainly taken up by the liver, 
whereas lipid-soluble compounds bypass the liver and are absorbed through the thoracic 
duct.12  Some ingested choline is metabolized by bacteria before it can be absorbed from the 
gut, primarily forming degradation products of betaine16 and trimethylamine.17-22  The rate of 
trimethylamine production is highest when relatively large amounts of choline are ingested.17  
Once absorbed, choline can be acetylated, phosphorylated, and oxidized.23  On the choline 
oxidase pathway, choline is metabolized to form betaine, in a two-step oxidation process.  
This pathway is described in detail within I.1.3 Betaine and Oxidation of Choline.    
I.1.2 Interconversion of Choline Metabolic Pathways   
I.1.2.1 Acetylcholine 
Only a small portion of dietary choline is acetylated,24-26 which occurs in a reaction 
catalyzed by choline acetyltransferase27, 28 (See Figure I.1) (Reviewed by Blusztajn et al.). 29 
Choline acetyltransferase is highly concentrated in the terminals of cholinergic neurons.27-29  
This pathway is important due to the role of acetylcholine as a neurotransmitter.3   
I.1.2.2 Phospatidylcholine 
The phosphorylation of choline is catalyzed by choline kinase using Mg2+ -ATP.30-32  
Phosphorylation of choline, making phosphorylcholine, is the first step in the major pathway 
for phosphatidylcholine synthesis on the Cytidine diphosphocholine (CDP)-pathway.33, 34  
Choline phosphate cytidylyltransferase (CTP) then catalyzes the synthesis of CDP choline 
from CTP and phosphocholine.  Once CDP choline is formed, it rapidly combines with 
diacylglycerol to form phospatidylcholine.  This metabolic pathway is displayed in Figure 
I.1.  This pathway serves an important function using choline as a precursor for the synthesis 
4 
of membrane phospholipids.8, 35  Phosphatidylcholine, the resultant product of the CDP-
pathway, is the predominant phospholipid (>50%) in most mammalian membranes.8  It 
accounts for roughly half of the phospholipids in cells and over half of serum 
phospholipids.35, 36  The rate of metabolism for the CDP-pathway is less rapid than that 
estimated for the choline oxidase pathway.37 
I.1.2.3 Sphingomyelin 
Sphingomyelin, a choline-phospholipid, is an important precursor for the generation 
of intracellular signals that is found in all tissues and lipoproteins.38, 39  Sphingomyelin 
metabolism has been reviewed extensively by Merril 199040 and Snook CF et al. 2006.41  
Briefly, sphingomyelin biosynthesis de novo involves ceramide formation from serine and 
acetylcholine, followed by the addition of the phosphocholine headgroup, which appears to 
originate from phosphatidylcholine (Figure I.1).40, 42 An alternative minor pathway for 
sphingomyelin synthesis includes the combination of the phosphocholine from CDP-choline 
with ceramide and acylation of sphingosylphosphocholine;40 however, this only accounts for 
an estimated 2-6% of the total biosynthesis.  Sphingomyelin can be hydrolyzed to reform 
choline.43 
I.1.2.4 Glycerophosphocholine 
Glycerophosphocholine is also involved in the interconversion of metabolic pathways 
(Figure I.1). Phospholipase B deacylates phosphatidylcholine, producing 
glycerophosphocholine and two free fatty acids44. Glycerophosphocholine can also be 
catabolized to form choline.     
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Figure I.1  Choline metabolism and links to methionine metabolism. The pathways 
described are all present in liver, with other tissues having one or more of these pathways.  
(Adapted from Zeisel, SH 20068 and Zeisel, SH 199045) 
 
I.1.3 Betaine and Oxidation of Choline 
Betaine (trimethylglycine), the trimethyletated compound of the amino acid glycine, 
is a quaternary ammonium compound and essential biochemical component of the 
methionine/ homocysteine cycle.  Betaine, a choline derivative, is important because of its 
role in the donation of methyl groups to homocysteine to form methionine.  Betaine is found 
in the diet  (See Table I.1) and it can be synthesized from choline (See Figure I.1).46  As 
previously mentioned, some ingested choline is metabolized by bacteria before it can be 
absorbed from the gut, primarily forming degradation products of betaine.16  In addition to 
the creation of betaine in the gut, a substantial portion of choline is oxidized to form betaine 
aldehyde which is then converted to betaine by the enzyme system choline oxidase.47  This 
irreversible two-step process,43 catalyzed by choline dehydrogenase, takes place in the 
Acetylcholine 
betaine  aldehyde 
dehydrogenase 
choline 
dehydrogenase 
CDP-choline: 
diacylglycerol 
cholinephosphotranserase  
Betaine 
Phosphatidylcholine 
phosphatidylethanolamine 
Betaine 
aldehyde 
 
Choline 
acetyltransferase 
Phosphocholine 
CDP-choline 
CHOLINE 
Choline kinase 
methionine 
betaine homocysteine 
methyltransferase 
S-adenosylmethionine 
phosphatidylethanolamine-N-
methyltransferase 
S-adenosylhomocysteine 
Sphingomyelin 
Glycero-
phosphocholine 
Ceramide Phospholipase B 
 homocysteine 
CTP: phosphocholine 
cytidylyltransferase 
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liver48-52 and kidneys (See Figure I.1). 48, 51, 53-56   This accounts for up to 50% of the 
destruction of ingested choline,16 while the remainder of dietary choline is used to make 
acetylcholine and phospholipids (e.g. phosphatidylcholine).57   Thus, production of betaine 
from choline oxidation diminishes the availability of choline to tissues and in the process, 
scavenges some methyl groups.  These methyl groups can be made available from one-
carbon metabolism, upon conversion to betaine.58  In this process, betaine homocysteine 
methyltransferase (BHMT) catalyzes the methylation of homocysteine, using betaine as the 
methyl donor (see Figure I.1).59-65  On an alternative pathway, 5-methyltetrahydrofolate 
homocysteine methyltransferase (MTHFR) regenerates methionine using a methyl group 
derived de novo from the one-carbon pool  (Figure I.2).59 MTHFR methionine regeneration is 
dependent upon vitamin B12 (B12) and folic acid66, 67. Deficiency of these nutrients has been 
associated with elevated plasma homocysteine concentrations.68, 69  Interestingly, when 
homocysteine flux is high, the capacity of the folate dependent pathway for methylation of 
homocysteine is exceeded and the choline/betaine pathway becomes increasingly 
important.70-72  However, when homocysteine flux is low, the folate-dependent methylation 
pathways are sufficient for homocysteine removal.70-72  After the homocysteine is 
methylated, methionine adenosyltransferase converts methionine to SAMe, which is the 
active methylating agent for deoxyribonucleic acid (DNA) methylation.63  Dietary 
methionine has been shown to decrease choline requirements; the hypothesized mechanism is 
through the replacement of choline as a methyl donor for the regeneration of S-
denosylmethionine.73, 74  Consequently, dietary choline demand is modified by the metabolic 
methyl-exchange relationships between choline and three nutrients: methionine, folate, and 
B12.4, 73  
7 
Through the metabolic pathways described above, it has been shown that choline 
functions as a precursor for acetylcholine, certain phospholipids, and betaine.4  Thus, choline 
participates in the methylation of homocysteine to form methionine, 59-61, 63 directly affects 
cholinergic neurotransmission (Section I.1.2 Interconversion of Choline Metabolic Pathways 
), 3, 27-29 and directly affects lipid transport from the liver (Section I.1.2 Interconversion of 
Choline Metabolic Pathways ).4, 8, 36, 75     
 
 
Figure I.2  Schematic representation of homocysteine metabolism (From Steenge et al.76)  
MTHFR, methylenetetrahydrofolate 
 
I.1.4 Non-dietary Choline Sources  
Aside from diet, the only other source of choline is through an endogenous pathway, 
named the Methytransferase Pathway, involving the de novo biosynthesis of 
phosphatidylcholine catalyzed by phosphatidylethanolamine N-methyltransferase (PEMT). 77 
8 
PEMT uses S-adenosylmethionine (SAMe) as a methyl donor for the sequential methylation 
of phosphatidylethanolamine to form a new choline moiety (See Figure I.1). 8, 78-83  This 
process is most active in the liver, however it also occurs in other tissues.75, 81 While there are 
three pathways for the biosynthesis of lecthin (CDP, Base Exchange, and Methyltransferase), 
only the Methyltransferase pathway results in a net synthesis of choline.  The CDP34 and 
Exchange 37, 84, 85 pathways only redistribute preexisting molecules (See Figure I.3).   
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Figure I.3  Pathways for the biosynthesis of lecithin.  The CDP-choline pathway and the 
Base Exchange pathway form lecithin by using pre-existing choline molecules (choline 
indicated by darker print), The Methyltransferase Pathway synthesizes lecithin by 
methylating phosphatidylethanolamine, thereby forming the choline moiety de novo.  CDP, 
Cytidine diphosphocholine; CTP, Choline phosphate cytidylyltransferase. (From Blusztajn, 
JK et al. 198186) 
 
I.2 Importance of Total Dietary Choline  
While choline can be biosynthesized de novo, the concentration of free choline in 
serum and tissues is heavily dependent on the dietary intake of choline.23, 27, 87-92  Existing 
research suggests that de novo synthesis is not sufficient to meet human requirements.  In 
adult humans, serum choline concentration have been shown to fluctuate within a small range 
when common foods are ingested.93 The administration of a single large dose of choline 
chloride (0.05 grams (g)/ kilogram (kg) of body weight) was found to elevate plasma choline 
concentration 300- 400%.73, 94  Hirsch MJ et al. 197894 observed peak choline concentrations 
within 3 hours post consumption of meals supplemented with choline; some elevation 
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persisted for up to 8 hours.94  Similarly, large doses of lecithin (0.3 g/kg of body weight) 
increased serum choline concentrations by as much as 400%, with elevations persisting for as 
long as 12 hours.94  Due to the metabolic pathways for the interconversion of the 
aforementioned choline forms (e.g. free choline, glycerophosphocholine, phosphocholine, 
phosphatidlycholine, and sphingomyelin) and the demonstrated effect of choline and 
phosphatidlycholine on serum choline levels, total dietary choline intake must be considered 
when examining dietary choline requirements.  While betaine and choline are also 
metabolically related, dietary betaine is considered separately, as the conversion from choline 
to betaine is irreversible.43   
Humans can become depleted of choline and betaine.5, 95  Choline depletion can affect 
health status, as it is a micronutrient that is essential for normal function of all cells.4  As 
detailed above, choline participates in the methylation of homocysteine to form methionine, 
59-61, 63 directly affects cholinergic neurotransmission,3, 27-29 and directly affects lipid transport 
from the liver.4, 8, 36, 75  There are a number of published comprehensive reviews of the 
metabolism and functions of choline.4, 96, 97   When deprived of dietary choline (from 1-4 
weeks), studies performed by da Costa et al. 200498 and Zeisel et al. 19915 reported that most 
adult men and postmenopausal women developed signs of organ dysfunction (fatty liver or 
muscle damage).  Choline deficiencies have also be associated with the reduced capacity for 
handling a methionine load, resulting in elevated homocysteine,70 a risk factor for 
cardiovascular disease99. In addition to these studies in humans, animal based research has 
shown choline deficient diets to be associated with infertility,7 bone abnormalities,100, 101 
decreased hematopoiesis,102 hypertension,103 and hepatic,5 renal,104, 105 pancreatic,4 memory,6 
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and growth disorders.7  Although many foods contain choline,43 there is at least a two-fold 
variation in the dietary intake of choline in humans.106-109  
I.2.1 Choline Adequate Intake  
Despite variability in human dietary choline intake and mounting evidence supporting 
a relationship between choline deficiencies and adverse health states, no studies have 
examined the relationship between chronic disease outcomes and habitual dietary choline and 
betaine intake.  Indeed, until very recently, the analytical data to address the dietary 
requirement for choline in the general population were insufficient.  Thus far, only an 
“Adequate Intake” has been determined, a value based on observed or experimentally 
determined approximations of nutrient intake in a group (or groups) of healthy individuals, 
when levels sufficient to meet the nutrient requirement of nearly all healthy members of a 
group cannot be determined (Recommended Dietary Allowance).23  In 1998 the U.S. Institute 
of Medicine’s Food and Nutrition Board established an Adequate Intake (AI) and tolerable 
Upper Limit (UL) for choline using data from liver damage prevention studies.23  Due to 
insufficient data, the recommended AI of 500 milligrams (mg)/day for adult males and 425 
mg/day for adult females (both aged 19 years and older) was based solely upon the results of 
one study conducted in healthy men (Zeisel et al. 19915).23  Further, the UL of 3.5 g/day for 
all adults was based on findings from a single case report of hypotension and several other 
studies involving cholinergic effects and fishy body odor after oral administration of large 
choline doses.23  In recognition of the dietary choline AI and UL estimate's shortcomings, the 
Institute of Medicine publication list recommends that high priority be placed on research 
which examines the effects of the use of graded levels of dietary intake of choline on 
parameters of health.23  This research priority could not be addressed until recently, as there 
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were no validated food composition data for betaine, choline, glycerophosphocholine, 
phosphocholine, phosphatidylcholine, and sphingomyelin prior to 2003.9, 43    
I.2.2 Choline and Betaine Conversion Tables 
In the early 1940s some data were generated, using now outdated methods, on the 
unesterified choline content of foods 110, 111 and in the early 1980s limited information was 
generated about the phosphatidylcholine content of foods.112  Prior to 2003 there was some 
information about the betaine concentration of foods,113-115 but no information concerning 
other esterified forms of choline (glycerophosphocholine, phosphocholine, 
phosphatidylcholine, and sphingomyelin).  The recent development of the United States 
Department of Agriculture (USDA) Special Interest database for choline and betaine in foods 
has provided a means to estimate choline and betaine intake from common foods.9, 43  To 
create the database, food samples were analyzed for betaine and the following choline 
contributing compounds: free choline, glycerophosphocholine, phosphocholine, 
phosphatidylcholine, and sphingomyelin.  Total choline content was calculated as the sum of 
the measured choline-contributing metabolites; acetylcholine and CDP-choline food 
concentrations were not estimated because dietary sources are negligible.9, 43  The database 
includes choline values (for individual metabolites and total choline) and betaine values for 
434 foods across 22 food categories, with food items arranged by food category.9  Quality 
assurance was monitored by duplicate sampling, and by the use of in-house control samples, 
and standard reference material with known choline content.9  This choline and betaine 
common food content database provides critical information needed to examine the 
relationship between choline and chronic disease endpoints. 
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I.2.3 Measuring Diet 
Included here for completeness is an overview of five common methods used to 
identify foods consumed in individual diets: direct observation; food record or diary; twenty-
four hour food recalls; interviews about food intake from the previous day; usual diet intake 
history.116, 117            
I.2.3.1 Direct Observation 
The use of direct observation is the only method of diet assessment for population 
based studies that assures the quantitative and qualitative validity of all nutrients 
consumed.117  Direct observation has been used to assess the validity of reported food intake 
in smaller studies with 1- 2 days of diet observation.118-120  While direct observation captures 
the participant’s current intake, it may not reflect usual intake.  Studies investigating the 
effects of usual diet on disease risk would require more prolonged direct observation; this 
method is often too expensive to employ for population based studies of diet and disease.117  
In addition to the associated costs, direct observation is particularly susceptible t to responder 
bias.  When participants are studied in the home a pseudo-artificial environment is created 
where they know their diet is being directly observed which could yield temporary behavior 
change.117, 121   
I.2.3.2 Food History 
An alternative to direct observation is the food history approach which is usually 
practiced as a refinement of the method described by Burke122 in the 1940’s.  The food 
history approach includes: a twenty-four-hour diet recall; a history of usual foods; data on 
food preparation.  This offers some time and cost savings over the direct observation method 
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since obtaining this information from participants usually requires a 1- 2 hour interview by a 
specially trained nutritionist.  Nonetheless, this method is also too costly for wide application 
and is very dependent upon the quality of the interviewer.117  Despite these limitations, the 
food history is used as a standard by which other methods not validated by observation are 
measured.117   
I.2.3.3 Twenty-four-hour Diet Recall 
The twenty-four-hour diet recall was designed to assess recent nutrient intake 
quantitatively.117, 123-126  This, 30-60 minute interview, is usually performed with a trained 
dietitian using food models and containers to assess quantity.117  This quantitative estimate of 
food intake reduces recall bias since it asks for diet within the past twenty-four hours.  While 
less expensive than the previous two methods, the twenty-four-hour diet recall is still 
relatively costly and requires trained interviewers.  Additionally, a twenty-four diet recall 
provides a snapshot of an individual’s diet which is probably not representative of their 
average dietary nutrient intake.117, 124, 127-130  The costs of performing multiple twenty-four-
hour food recalls to address the aforementioned shortcomings can be prohibitive for larger 
population based studies.  Number of recall days required to reliably place subjects in the 
same quintile of intake for some nutrients ranges from 3-7 for dietary fat124, 127 to 17-19 
recalls for calcium.129 
I.2.3.4 Food Record or Diary 
One dietary assessment tool that does not require a dietitian for data acquisition is the 
food record or diary.  Food records are usually compiled, by the participant, over 3-7 days 
alternate days, insuring that one-day was a Saturday or Sunday.  This could potentially avoid 
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the costs of an interviewer; however, the food record is more accurate when participants are 
trained by dietitians in how to estimate quantity and record intakes.117  Consequently, this 
method may not be less costly than the aforesaid approaches.  Some limitations of this 
method revolve around its participant driven nature.  The validity of food records can be 
affected by compliance issues, bias due to self-report, and respondent’s perceptions.  
Logging the details of every food item consumed can be a tedious task.  Compliance rates, 
accurately logging all foods, can be affected by differences in the level of vigilance by which 
participants complete the records.  More importantly, characteristics affecting vigilance may 
also be related to diet patterns.  Additionally, reporting could be biased since the participant 
knows that their complete 3-7 day diet will be viewed by another person.  This could result in 
some underreporting of food items; like the compliance issue, this may be associated with 
diet patterns.  Finally, it is well known that behavior modification can be induced by just the 
act of recording all food consumed for greater than one or two consecutive days.117  Despite 
these shortcomings, the food record is often used as the gold standard for validating other 
methods in the absence of food history or direct observation.117  
I.2.3.5 Food Frequency Questionnaire 
As stated previously, the twenty-four hour recall, diet record, and direct observation 
are generally expensive and unrepresentative of usual intake when only a few days are 
assessed131.  The food frequency questionnaire, first touched upon by Burke (1947)122 and 
further developed during the 1950s,132-135 represents an attempt to obtain a self-administered, 
inexpensive, and rapid estimate of usual intake.117  With further substantial refinement in the 
1980s and 1990s131 the Food Frequency Questionnaire (FFQ) has become the most 
commonly utilized tool for assessing diet of individuals in epidemiologic settings.121  The 
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FFQ is directed to the average long-term dietary exposure (e.g. intake over weeks, months, 
years).121  Most FFQs collect information on the consumption of roughly 60-130 food 
items,131 depending upon the version. The information on foods items consumed is 
aggregated across all meals, and quantification of diet is restricted to categories of 
consumption (e.g. never, once a month or less, 2-3 times per month, etc.).131  Through the 
collection of these details, the FFQ provides estimates of dietary exposure that are of 
conceptual interest in most applications, which is average intake over an extended period of 
time121.  Further, estimates of habitual diet would likely be expected to be a better predictor 
of chronic disease than would a single day’s diet.117    
When compared to the other diet assessment tools, the FFQ is more cost effective and 
representative of usual diet.  It can be administered by personal interview, self-administered, 
by telephone, or through the mail thus greatly reducing cost.136  The FFQ asks about usual 
diet over an extended period of time, allowing it to be more representative of usual intake 
than a short diet record or twenty-four-hour food recall.117 Also, examining usual diet over an 
extended period of time tends to reduce misclassification, when compared to short term diet 
observation, by increasing the chances of correctly ranking subjects (e.g. placing in quintiles 
by usual intake), which is more likely to reflect a diet-disease association.117, 137, 138   
There are also some limitations to the FFQ method.  Completion of a short non-
quantitative self-administered questionnaire requires a certain level of literacy.117 The list of 
foods specific items tends to be fairly culture specific. Due to the limited number of food 
items in a FFQ some dietary habits may be missed.117 The FFQ relies on fixed or subjective 
definitions of small, medium, or large portions making the size estimation more semi-
quantitative.  Usual diet estimations from the FFQ allow for ranking of individuals by 
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consumption, but do not provide for more precise estimation of quantities.  Consequently, the 
combination of missing foods and semi-quantitative methods limits the accuracy of the 
estimated caloric intake.117    
I.2.3.6 Measurement Error in Dietary Assessment 
In addition to the instrument specific considerations listed above, all of these dietary 
assessment tools are subject to varying degrees of measurement error.  While there are 
numerous sources of error, they can be roughly grouped into two general types: random and 
systematic.139  Each of these two errors can be further subdivided into within and between 
errors, resulting in four basic types of measurement error: random within-person, systematic 
within-person, random between-person, and random within-person.139, 140  These four general 
types of errors are depicted in a figure from Willett 1989 (See Figure I.4) 141.   
 
Random within-person. Random within-person error is comprised of day-to-day 
fluctuations in dietary intake due to daily changes in food intake and errors in the 
measurement on any given day (Figure I.4) 139.  When only 1- 2 days are measured, a 
subject’s true long-term intake is likely to be misrepresented/ misclassified.142  Within-person 
dietary variation causes the observed correlation of the dietary exposure and disease outcome 
to be attenuated. 124, 143  Random within-person error can be reduced through the use one or 
more replicate measurements obtained from an individual.124, 143, 144  A single measurement is 
an unbiased estimate of the true exposure and the mean of n replicate measurements is also 
an unbiased estimate of the true exposure, but with a smaller variance.145  Additionally, a 
large number of replications will approach a subject’s true long-term exposure.145  
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Systematic within-person. Repeated measures of diet may also be subject to systematic 
error in addition to random error.  In the presence of systematic within-person error, 
unbiasedness does not hold and the mean of many repeated measures will not necessarily 
converge toward a person’s true intake (Figure I.4).145  Therefore systematic within-person 
error is another valid concern when examining dietary assessment tools.  This is can be in the 
form of a consistent incorrect estimation of the true diet due to design aspect associated with 
the instrument.  Using dietary questionnaires can possibly result in systematic within-person 
error because repeated administrations may consistently under- or over- estimate intake due 
to conscious or unconscious under- or over- reporting.145 This can be the result of such things 
as consistent misinterpretation of a question by a subject, or the omission of a food item from 
the questionnaire that is important for some individuals.139, 145 Estimates of systematic 
within-person error are obtained through the comparison of the observed measurement with 
an independent measure of true exposure, which measures the validity.145  However, the 
majority of studies considering measurement error use the assumption that within-person 
error is strictly random since much of statistical theory is based on the assumption of random 
error and systematic error is considerably more difficult to measure.139   
 
Random between-person. When measuring diet among a group of persons, between-person 
error is also of concern.139  Random between-person error can occur when only a few 
replicate measures per subject are obtained in the presence of random within-person error or 
the consequence of systematic within-person errors that are randomly distributed among 
subjects.139  Random between-person error implies that an overestimation for some 
individuals is counterbalanced by an underestimation for others so that the mean for a large 
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group of participants is the true mean of the group (Figure I.4) 139.  However, this will result 
in a net overestimation of the standard deviation for the group.139 
 
Systematic between-person. Systematic between-person error can occur due to systematic 
within-person error that affects subjects non-randomly.139  This will lead to an incorrect mean 
value for a group of persons.139  Systematic between-person errors occur frequently and can 
have many causes (e.g. the omission of a commonly eaten food from a standardized 
questionnaire; the use of an incorrect nutrient composition value for a common food).139  
Systematic within-person error infrequently affects all individuals equally.139  While the 
omission of a commonly eaten food on a standardized questionnaire or the use of an incorrect 
nutrient composition value for a common food will affect individuals in the same direction 
(Figure I.4), it will not affect them to the same degree since the consumption of these foods 
will differ among subjects.141  Many times, random and systematic between person errors 
exist in combination.139   
 
 All four general types of error are described above for completeness.  However, this 
proposal is designed to estimate and adjust for the effects of random and systematic within-
person measurement error.  Systematic between-person error will indirectly be examined as 
both of the components that contribute to it will be considered (random within-person error 
and systematic within-person). 
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Figure I.4 Types of error common in nutritional epidemiology studies from Willett 1989141 
 
I.2.3.7 Implementation of Dietary Assessment Tools in the Study of Chronic Disease 
In summary, dietary intake can be estimated with diverse tools.  Some assessment 
tools involve opened ended records or recalls on specific days (i.e. twenty-four food recalls; 
direct observation; four-day food records), while others are designed to examine habitual 
intake using finite portion, food items, and frequency of consumption metrics (i.e. FFQ).  It 
has been argued that an individual’s stable, habitual nutrient intake is the more relevant 
exposure in epidemiologic studies designed to assess the impact of long-term dietary habits 
on chronic disease.139 Although prolonged diet recordings per subject provide the ideal 
standard, this process is costly and of limited applicability in the setting of population 
studies.  The FFQ provides a cost effective means for estimating long-term diet and is widely 
used in epidemiologic studies for such purposes.131  Therefore, the FFQ in combination with 
the choline and betaine common food content database provides critical information needed 
to examine the relationship between choline and chronic disease endpoints. 
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I.3 Choline/Betaine and Cancer  
Choline, methionine, and folate are interconnected on the methylation metabolic 
pathway that produces methionine from homocysteine (See Figure I.5).  As previously 
mentioned (Section I.1.3 Betaine and Oxidation of Choline), oxidation of choline to betaine 
produces methyl groups used to convert homocysteine to methionine (Figure I.1).58-65  
Methionine adenosyltransferase then converts methionine to SAMe, which is the primary 
methyl donor for numerous biochemical reactions throughout human tissue (See Loenen 
2006 review146), including DNA methylation.63 
Rats fed diets deficient in dietary choline and betaine have decreased SAMe 
concentrations,147, 148 and DNA hypomethylation has also been observed in rats during 
choline deficiency with adequate dietary levels of methionine.149, 150  Deficiencies in dietary 
folate and B12 may also lead to decreases in SAMe concentrations through effects on the 
folate dependent pathway (See Figure I.2). 151 Rat studies have consistently shown that diets 
deficient in the methyl donors choline, folate, methionine and B12 induce genomic and 
protooncogene DNA hypomethylation and elevated steady-state levels of corresponding 
mRNAs.149, 152-157 
Methylation is the enzymatic addition of a methyl group to the carbon-5 position of 
cytosine.158, 159  Methylation of DNA is essential for the regulation of gene expression, and in 
turn cell differentiation.160-165  Specifically, methylation regulates genetic elements including 
promoters, enhancers, insulators, and repressors usually by suppressing their function.161 
Additionally, methylation within gene deficient regions, such as in pericentromeric 
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heterochromatin, appears crucial for maintaining the conformation and integrity of the 
chromosome.161, 166   
Epigenetic events are believed to play a significant role in the development and 
progression of cancer.  Hypermethylated regions have been found in virtually every type of 
human neoplasm and are associated with the transcriptional silencing of genes.167, 168  
Hypomethylation changes similar to those induced by dietary choline, methionine, and folate 
deficiencies, have also been observed in tumors.  They are similar to those induced by dietary 
choline; methionine; folate deficiencies.   
It has thus been hypothesized that hypomethylation of non-promoter regions of DNA 
and of structural elements, such as centromeric DNAs, cause enhanced genomic 
instability.169, 170  This is supported by the observation that many human tumors have similar 
losses of DNA methylation and chromosomal structural changes in these regions.169, 171  In 
humans germ-line mutations in DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3B), 
which encodes DNA methyltransferase 3β, an enzyme that catalyses DNA methylation, are 
associated with decreased DNA methylation and the immunodeficiency, centromeric 
instability and facial abnormalities (ICF) syndrome.172-174  ICF patients have a loss of 
methylation at selected centromeric regions and profound chromosomal structural changes.169  
Further supporting the enhanced genomic instability hypothesis, increased levels of gene 
deletion have been reported in mouse embryonic stem cells that are deficient in DNA 
methyltransferase 1.175 
Hypomethylation may also influence carcinogenesis by modifying gene expression, 
including increased expression of oncogenes165, 176 and may be a crucial factor facilitating 
clonal expansion of the progenitor cells that lead to tumors.177  Ray et al. showed that rat 
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liver cells from the population which initially exhibited hypomethylation later advanced to 
yield the tumors that formed, as observed from tissue samples.178 Finally, studies in humans 
have found that the extent of genome-wide hypomethylation in tumors parallels closely the 
degree of malignancy, though this is tumor-type dependent.161  In breast, ovarian, cervical, 
and brain tumors, for example, hypomethylation is seen to increase progressively with 
increasing malignancy grade.179, 180  The previously mentioned lines of evidence reflect 
findings from association studies, and it is important to note that a cause and effect 
relationship has yet to be established.     
Thus, hypomethylation has been linked to transformation, tumor progression, and 
oncogene expression,177-179, 181-184 thereby providing a basis for primary tumor growth.185 
Several studies have thus provided evidence indicating that global hypomethylation serves as 
an early, and fairly consistent, event in carcinogenesis.169, 186  Among these, cross-sectional 
studies have reported associations between DNA hypomethylation and colorectal,187 
breast,180 and lung cancer.161, 188 
 
 
 Figure I.5  The interconnecting DNA methylation pathways of choline, methionine and 
methylene tetrahydrofolate (THF). Taken from Niculescu and Zeisel 200258 
24 
I.4 Choline/Betaine and Cardiovascular Disease 
Dietary betaine and choline intake may also be associated with coronary heart disease 
(CHD) and stroke risk through the homocysteine methylation pathway. Homocysteine, a 
breakdown product of methionine, is further degraded to cysteine through B6 dependent 
reactions.189 Alternatively, homocysteine is methylated to form methionine. This methylation 
reaction can be catalyzed either by betaine homocysteine methyltransferase, where betaine is 
the methyl donor for the reaction or methionine synthase (Figure I.2).62   In general, there is a 
graded and direct association between plasma total homocysteine levels and cardiovascular 
disease, including coronary vascular disease and cerebral vascular disease and arterial 
thromboembolism.190-201  However, this association has not been confirmed by population 
based studies or clinical trials of homocysteine modification via supplementation with folic 
acid, vitamin B6 (B6) and vitamin B12 (e.g. the Vitamin Intervention for Stroke Prevention 
(VISP)202, Norwegian Vitamin Trial (NORVIT) 203, Heart Outcomes Prevention Evaluation 
(HOPE2)204 studies).  
 
I.4.1 Choline/Betaine and Total Homocysteine 
Homocysteine, a thiol-containing amino acid, is an intermediate of the intracellular 
metabolism of methionine205, 206 on the methylation pathway connecting choline, methionine 
and folate (Figure I.5).58-65 When exported into the blood, homocysteine is present in the 
reduced form (homocysteine) and the oxidized state (i.e. the disulfides homocysteine and 
cysteine-homocysteine).205, 207 All these forms, whether free or bound to proteins, contribute 
to total homocysteine, also called, homocyst(e)ine.205 Only a small fraction of total 
homocysteine is present as nonprotein bound, reduced homocysteine.205  Hereditary, dietary 
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deficiencies and enzymatic deficiencies on either the methylation pathway or transulfuration 
to cysteine result in elevated levels of total homocysteine.  Elevated total homocysteine is 
clinically referred to as homocysteinemia (elevated levels in blood) or homocystinuria 
(elevated levels in urine).205, 208-212    
I.4.2 Proposed Mechanisms Linking Total Homocysteine and Cardiovascular Disease 
Risk 
 
The mechanisms by which homocysteinemia is associated with atherosclerosis are not 
fully understood.213 There are a few plausible mechanisms by which relatively elevated 
plasma total homocysteine may contribute to vascular disease, including mechanisms related 
to increased thrombosis, impaired thrombolysis,214 endothelial dysfunction, 213, 215, 216 and 
oxidation of low-density lipoprotein (LDL) 202, 217 (Reviewed in McCully 1996218 and 
Stamler and Slivka 1996216).  Of these mechanisms, only the impaired thrombolysis and 
endothelial dysfunction hypotheses could plausibly be affected by dietary choline and betaine 
intake.217  Randomized clinical trials of homocysteine reduction through various 
supplementation combinations of -folic acid, B12, and B6; -folic acid and B12; -B6 showed no 
appreciable reduction in either LDL or total cholesterol levels when each combination was 
compared to the placebo treatment group.202-204  These findings are supported by the research 
reported by Dalmeijer et al. 2007from the PROSPECT-EPIC study.108 
I.4.2.1 Homocysteine and Increased Thrombosis and Impaired Thrombolysis 
Multiple hypotheses have been put forth regarding the role of homocysteinemia in 
venous thrombosis and atherosclerosis.214  Among them, it has been posited that 
homocysteine has a toxic effect on the vascular endothelium and on the clotting cascade.219  
Based on numerous studies that have reported on homocysteine-induced altered endothelial 
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cell function.  Enhanced Factor V activity, decreased protein C activation, and diminished 
fibrinolysis 220-222 are among the observations that provide evidence of a vascular coagulant 
mechanism in the pathogenesis of hypercoagulability associated with 
hyperhomocysteinemia. 
I.4.2.2 Homocysteine and Endothelial Dysfunction 
In addition to the mounting evidence of an effect of hyperhomocysteinemia on 
hypercoagulability, there is also an increasing body of research which provides evidence that 
chronically elevated total homocysteine also has adverse effects on the endothelial 
function.213  Studies have reported that chronically elevated homocysteine concentrations are 
associated with impaired flow-mediated endothelium dependent vasodilatation in children223 
with severe hyperhomocysteinemia and in adults224, 225 with moderate 
hyperhomocysteinemia.213  It is not completely known how homocysteinemia contributes to 
endothelial dysfunction.223, 224  While the causal association has been established, the 
mechanism of action has yet to be elucidated.  In vitro studies have provided some clues to 
the nature of the relationship.  Specifically, while initial exposure of cultured endothelial 
cells to homocysteine leads to the formation and release of nitric oxide, S-nitrosothiols, and 
S-nitrosohomocysteine,226 continued exposure leads to reduced production of nitric oxide or 
inactivation of nitric oxide226, 227 by superoxide anion radicals and hydrogen peroxide.226, 227  
This impaired availability of nitric oxide, which has potent vasodilator and platelet-inhibitor 
properties, leaves the endothelium vulnerable to unopposed homocysteine-mediated 
oxidative damage.213, 228  However, these studies could not establish whether endothelial 
dysfunction was caused by elevated homocysteine by atherosclerotic disease associated with 
elevated homocysteine.223, 224  To this end, Chambers et al 1999 studied vascular endothelial 
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responses to acutely elevated homocysteine concentrations in healthy human subjects, and 
found that an elevation in homocysteine concentration was associated with an acute 
impairment of endothelial function that was prevented by pretreatment with vitamin C.  This 
finding supports the hypothesis that adverse effects of homocysteine on vascular endothelial 
cells are mediated through oxidative stress mechanisms.213    
I.4.3 Research in Total Homocysteine Reduction through Betaine Supplementation 
Folic acid, B6, and vitamin B12 can reduce plasma total homocysteine,229, 230 and 
possibly help reverse elevated total homocysteine-related endothelial injury.213, 215  
Individuals with relatively higher plasma levels or dietary intake of folate and vitamin B6 
have a decreased risk of CHD.231-234  Of the aforementioned B vitamins, studies have shown 
folic acid to be the strongest dietary determinant of homocysteine, with daily 
supplementation (between 0.5 to 5.0 mg) typically lowering plasma homocysteine levels ~25 
percent, Vitamin B12 supplementation (at least 0.4 mg daily) further lowering levels by about 
7 percent, and vitamin B6 supplements lowering homocysteine after methionine loading.204, 
230, 235  
Folic acid fortification of enriched grain in the U.S. began in 1996 and was mandated 
by January 1998 in hopes of reducing the risk of neural tube defects in newborns.  The 
fortification was associated with a reduction in the population mean level of total 
homocysteine in the U.S.,236 and a three-fold acceleration in the decline of stroke mortality, 
and was subsequently estimated to have prevented 17,000 deaths from ischemic heart disease 
and 31,000 stroke related deaths each year.237   However, these estimates are not supported 
by population based studies or clinical trials of homocysteine modification via 
supplementation with folic acid, B6, and B12 (e.g. VISP202, NORVIT 203, HOPE2204).  As 
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previously mentioned homocysteine is an intermediate of the intracellular metabolism of 
methionine205, 206 on the methylation pathway on which choline, methionine and folate 
interconnect (Figure I.5). 58-65 
Presumably, dietary choline and betaine intake could have a significant influence on 
total homocysteine levels.  This is of interest since, when homocysteine flux is high, the 
capacity of folate dependent pathway for methylation of homocysteine is exceeded and the 
choline/betaine pathway becomes increasingly important.70-72  While total homocysteine 
lowering with B vitamin supplementation has been thoroughly researched in epidemiologic 
and clinical trial studies, research into the effects of betaine supplementation have been 
mainly limited to the clinical case reports.76 Clinical case reports have been published on the 
success of betaine treatment in combination with folic acid supplementation in normalizing 
total homocysteine concentrations in hyperhomocysteinemia patients with genetically 
induced errors in homocysteine metabolism (e.g., cystathionine, β-synthase deficiency, 5, 10- 
MTHFR deficiency).238-241 These studies report on a small number of patients with extremely 
elevated total homocysteine levels; there are few data on the effects of betaine 
supplementation in individuals with normal to mildly elevated homocysteine levels. In 
smaller population-based studies, Brouwer et al. 2000242 and Schwab et al. 2002243 reported 
that daily ingestion of 6 g/day betaine for 2 weeks and 6 g/day for 12 weeks, respectively,  
was associated with a 8-9% reduction in mean fasting plasma total homocysteine levels.   
Further, Steenge et al. 200376 conducted a study of the effects of prolonged betaine 
versus placebo or folic acid supplementation on fasting plasma homocysteine concentrations 
and plasma homocysteine levels after methionine loading (ingestion of 100 mg methionine 
/kg body mass) in middle-aged men and women with mild elevations of homocysteine.76  
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When compared to the placebo group, fasting plasma homocysteine changed by -1.8 
micromoles (µmol)/ liter (L) (95% confidence interval [CI]: -3.6, 0.0) in the betaine group 
and by -2.7 µmol/L (95% CI: -4.5, –0.9) in the folic acid group.76  Interestingly, betaine 
suppressed the total area under the plasma homocysteine-time curve after methionine loading 
by 221 µmol x 24 hours/L (95% CI: -425, –16) compared with placebo, whereas folic acid 
had no effect when compared to the placebo treatment (See Figure I.6).76  All estimates 
presented by Steenge et al. were unadjusted.  Overall, daily ingestion of 6 g/day of betaine 
for 6 weeks was associated with an 11% decrease in mean fasting plasma homocysteine 
concentrations and a 40% reduction in mean plasma homocysteine peaks 6 hours post 
methionine load (See Figure I.6).76  This further supports the folate dependent pathway for 
methylation of homocysteine is exceeded and the choline/betaine pathway becomes 
important when homocysteine flux is high.70-72  Some recent studies have additionally 
examined whether total homocysteine lowering via betaine supplementation is associated 
with subsequent reductions in blood lipid levels108, 244 and cardiovascular disease risk.108     
Olthof et al. 2005244 combined data from four different placebo-controlled 
intervention studies to investigated the effects of supplementation of three homocysteine-
lowering nutrients (betaine, choline, and folic acid) on blood lipid concentrations in modestly 
hyperhomocysteinemic patients.  Phosphatidylcholine (2.6 g/day), betaine (1.5, 3, or 6 g/day) 
and folic acid (0.8 mg/day) treatment for 6 weeks lowered plasma homocysteine by 12% to 
20%.  However, betaine treatment appeared to be positively correlated with LDL, such that 
participants receiving a 1.5 g/day betaine dose had an mean LDL that was 0.1 millimoles 
(mmol)/ L higher than the placebo treatment group, while mean levels among those receiving 
3 g/day were 0.2 mmol/L higher; and levels among those receiving 6 g/day were 0.4 mmol/L 
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higher.244  Zeisel 2006245 argues that these differences are possibly an artifact attributable to 
differences in the randomization of subjects. 
I.4.4 Studies of the Association between Ingested Choline and Betaine and 
Cardiovascular Disease Risk 
 
Extending the work of Olthof et al. 2005, Dalmeijer et al. 2007108 investigated the 
association between dietary intakes of folate, betaine and choline and the risk of 
cardiovascular disease (CVD) in 16,165 Dutch postmenopausal women from the Dutch 
European Prospective study Into Cancer and nutrition (PROSPECT–EPIC) cohort.  
Participants were followed for an average of 8.1 years.108  They also examined associations 
between dietary intakes of folate, betaine and choline and plasma homocysteine 
concentrations and cholesterol concentrations in a subsample of 1,610 women (homocysteine 
in a subsample of 903 women) were also examined.108  The usual dietary intake of 178 food 
items in the year preceding enrollment was estimated using a FFQ246, 247 with choline and 
betaine contents in individual foods estimated from the available data of the USDA Special 
Interest database for choline and betaine in foods.9  
Baseline nutritional characteristics of these women are summarized in Table I.2. 
Dalmeijer et al. 2007 did not find an association between betaine and homocysteine 
concentrations, and intakes of choline and folate had only weak inverse associates with 
plasma homocysteine concentrations,108 which they attributed to narrow ranges of intakes in 
the study population.  They did not observe the same betaine associated LDL lowering that 
Olthof et al. 2005 reported; however, higher betaine intake was associated with lower HDL-
cholesterol (difference between fourth and first quartile -0.06± 0.03 mmol/l, 95% CI: -0.11;-
0.01), but not with homocysteine concentrations. Higher choline intake was associated with 
31 
lower homocysteine levels (difference between fourth and first quartile – 0.87±0.35 mmol/l, 
95% CI: -1.56; -0.19).108  They considered the following variables as confounders: intake of 
energy, proteins (energy-adjusted), saturated fats (energy-adjusted), monounsaturated fats, 
polyunsaturated fats (energy-adjusted), alcohol (energy-adjusted), B2 (energy-adjusted), B6 
(energy-adjusted), B12 (energy-adjusted), betaine (energy-adjusted) and choline (energy-
adjusted).  In the multivariable adjusted models, choline, betaine and folate intakes were not 
associated with total CVD, CHD or cerebrovascular disease.108  Again, this could be 
attributed the narrow ranges of choline, betaine and folate intakes in this study population.   
Research similar to Dalmeijer et al. 2007 was also conducted within the 
Atherosclerosis Risk in Communities (ARIC) study, where Bidulescu et al. 2007109 assessed 
the association of dietary intake of choline and betaine with incident CHD.  This study differs 
from Dalmeijer et al. 2007 in that it was conducted in a large biethnic prospective cohort 
with participants of both genders and adjusted for dietary intake measurement error.  Study 
participants (n=14,430), aged 45 and 64 at enrollment, were recruited from Forsyth County, 
North Carolina; Jackson, Mississippi; suburbs of Minneapolis, Minnesota; Washington 
County, Maryland.248  Participants were followed-up for an average 14 years (1987–2002) 
for incident CHD events.248  Usual dietary choline and betaine intake, for the year preceding 
enrollment, was quantified at the baseline visit (1987–1989), with a 66-item version of the 
Willett semi-quantitative FFQ.249  As in Dalmeijer et al. 2007, the choline and betaine 
contents in individual foods were estimated USDA Special Interest database.9  In addition to 
the baseline FFQ, a random sample of 1,004 participants whose dietary intake was measured 
three years after the ARIC baseline was also examined to assess the reliability of the FFQ for 
choline (choline plus betaine), folate, methionine and total energy intake.  The results from 
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the reliability study were subsequently used for regression calibration to correct for 
measurement error of the aforementioned variables.145, 250, 251 
The baseline nutritional characteristics are summarized in Table I.3.  Hazard ratios 
(HR) were calculated, per quartiles of dietary intake, using Cox proportional hazard 
regression considering the following variables as confounders: age, sex, education, dietary 
folate, methionine, B6 vitamin and cholesterol, race, diabetes, ARIC center, menopausal 
status (reported cessation of menses), and a series of CHD risk factors such as smoking, 
hypertension, body mass index (BMI) and family history of CHD.  The results of these 
analyses are represented in Table I.4.  No effect measure modification was detected by sex, 
menopausal status, race, ARIC center, education, or folate intake (analyzed as a continuous 
variable).  Compared with the lowest quartile of intake, incident CHD risk was slightly 
higher in the highest quartile of choline and choline plus betaine, HR = 1.22 (95% CI: 0.91, 
1.64) and HR = 1.14 (95% CI: 0.85, 1.53).   Additionally, no associations were observed 
between dietary choline intake and incident CHD after adjustment for measurement error 
(data not shown).     
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Figure I.6  Plasma total homocysteine response in humans after the ingestion of 100 mg methionine/kg body mass before (A) and on 
the last day of treatment (B). Treatment consisted of the ingestion of 3 g of betaine (n = 12), 400 µg folic acid with 3 g of placebo (n 
= 12) or 3 g of placebo (n = 10) twice each day for 6 weeks. Values are means ± standard error. The dotted line represents the placebo 
group excluding the subject with an abnormal plasma homocysteine response after the second methionine challenge Steenge et al. 
2003.76 
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Table I.2  Baseline nutritional characteristics of the European Prospective study Into Cancer 
and nutrition women (n=16,165) (From Dalmeijer 2007108).   
Multivitamin status n (%) 
   Never 11,753 (72.7)  
   User  1,146 (7.1) 
   Unknown  3,266 (20.2) 
   
Dietary Intake Mean ± s.d. 
Betaine, (mg/day) 214± 74 
Choline, (mg/day) 300  ± 51  
Folic acid, (µ/day)  195 ± 40 
Energy, (kcal/day)  1,798 ± 436 
Protein, (% of energy)  16.1 ± 2.41 
Carbohydrates, (% of energy)  44.7 ± 6.4 
Total fat, (% of energy)  35.6 ± 5.5 
Saturated fat, (g/day)  29 ± 5 
Monounsaturated fat, (g/day) 26  ± 5 
Polyunsaturated fat, (g/day) 13  ± 4 
Cholesterol, (mg/day) 199 ± 54 
Dietary fiber, (g/day)  22 ± 4 
Alcohol, (%of energy)  3.6 ± 4.9 
Vitamin B2,(mg/day)  1.6 ± 0.4 
Vitamin B6,(mg/day)  1.5 ± 0.2 
Vitamin B12,(mg/day)  4.3 ± 1.8 
s.d. standard deviation 
 
 
Table I.3 Distribution of baseline nutritional characterisitics of the ARIC Study population 
(N = 14,430) according by gender (From Bidulescu 2007109). 
Characteristic Men Mean ± s.d.  
Women 
Mean ± s.d. 
    
Choline intake, mg/day   332.1 (-124.7)  294.2 (-111.9) 
Betaine intake, mg/day   118.1 (-55.4)  102.4 (-47.1) 
Alcohol intake, g/day   10.16 (-17.83)  2.9 (-7.21) 
Dietary cholesterol, mg/day   278.2 (-139.4)  230.2 (-112) 
Dietary methionine, g/day   1.74 (-0.66)  1.63 (-0.66) 
Dietary fiber, g/day   17.3 (-7.94)  16.9 (-8.02) 
Dietary folate, µg/day   234.4 (-102.4)  221.5 (-100.2) 
Dietary saturated fatty acid, g/day 24.2 (-10.6)  19.9 (-9.2) 
s.d. standard deviation 
 
 
 
 
  
Table I.4  Hazard rate ratios (and 95% CI) for CHD across quartiles of dietary intakes among 14,430 participants in the ARIC Study 
(From Bidulescu 2007109). 
*In models #1, adjustment was made for age, sex, education, total energy intake, and dietary folate, methionine and vitamin B6. 
†In models #2, adjustment was made for all of the above plus race, diabetes status, ARIC field center, menopausal status and dietary 
cholesterol. 
‡In models #3, adjustment was made for all of the variables listed in models #2 plus dietary intake of saturated fatty acids, animal fat, 
dietary fiber and animal protein. 
 
 
 
 
 
 
 
  Quartile (Q) of dietary intake 
  Q1  Q2  Q3  Q4 
  (N=3607)  (N=3608)  (N=3608)  (N=3607) 
         
Choline   <217 mg/day  217–283 mg/day  283–363 mg/day  >363 mg/day 
Model #1*   Referent  0.89 (0.73, 1.08)  1.11 (0.90, 1.38)  1.22 (0.91, 1.64) 
Model #2†   Referent  0.84 (0.69, 1.03)  1.03 (0.82, 1.29)  1.05 (0.76, 1.45) 
Model #3‡   Referent  0.93 (0.76, 1.13)  1.10 (0.87, 1.37)  1.09 (0.79, 1.50) 
Total choline   <298 mg/day  298–384 mg/day  384–486 mg/day  >486 mg/day 
Model #1   Referent  0.91 (0.75, 1.10)  1.07 (0.86, 1.33)  1.14 (0.85, 1.53) 
Model #2   Referent  0.87 (0.72, 1.05)  1.01 (0.81, 1.26)  0.99 (0.73, 1.35) 
Model #3‡   Referent  0.86 (0.67, 1.11)  1.21 (0.97, 1.52)  1.14 (0.83, 1.56) 35 
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I.5 Significance  
Thus far, two studies (Bidulescu et al. 2007109 and Dalmeijer et al. 2007108) have 
examined the relationship between cardiovascular disease outcomes and habitual dietary 
choline and betaine.  There have been no studies examining these same exposures with 
respect to lung, colorectal and breast cancer development.  Indeed, until very recently, there 
have been insufficient compositional data to address the dietary requirement for choline in 
the general population.  Thus far, only an “Adequate Intake”, based on studies of liver 
damage prevention, has been suggested by the Institute of Medicine.23   The recent 
development of the USDA Special Interest database for choline and betaine in foods has 
provided consumers and researchers with a means to estimate choline and betaine intake 
from common foods.9, 43   The goal of the present study is to examine the distributions of 
reported habitual choline and betaine intake in both the Women’s Health Initiative (WHI) 
Observational Study (OS) and the Dietary Modification (DM) trial at baseline.  It will also 
estimate the associations between reported habitual choline and betaine intakes and the 
incidence of several important cardiovascular and cancer outcomes in the OS. 
I.5.1 Cardiovascular Disease 
CVD is the leading cause of death among adults within the U.S.252 and in the majority 
of regions of the world.253, 254 According to the National Vital Statistics Reports, heart 
disease and stroke were the leading causes of death in the U.S. during 2003, accounting for 
approximately 34% of all deaths.252  Approximately half of all coronary and cerebrovascular 
deaths each year occur in women.252  An estimated 79.5 million American adults (1 in 3) 
have at least one type of CVD; of these, 37.5 million are estimated to be age 65 or older 
37 
(extrapolated to 2004 from NCHS NHANES 1999–2004).255  The Framingham Heart Study 
estimated the lifetime risk of CHD (angina pectoris, coronary insufficiency, myocardial 
infarction, or death from coronary heart disease) for those CHD-free at age 40 to be 49% for 
men and 32% for women.  For those who were CHD-free at age 70, the risk was 24% for 
women and 35% for men.256   
I.5.2 Women’s Health Initiative Study 
The proposed study will use data from the WHI to address gaps in knowledge about 
the distribution of dietary betaine and choline intake.  The WHI OS and clinical trial 
components (CT) components are composed of postmenopausal women that ranged in age 
from 50 to 79 years old at enrollment (from October 1993 through December 1998).  This 
age group is ideal for examining effects of dietary exposures on the risk of, breast, lung, and 
colorectal cancer, and cardiovascular diseases because of the age dependency of these 
chronic diseases.  The longitudinal nature of the WHI OS will allow us to establish the 
temporality of relations between habitual dietary choline and betaine intakes and the 
proposed chronic disease endpoints.  Details of this study are further discussed in Section 
III.2 Design. 
I.5.3 Public Health Significance 
Choline and betaine are nutrients necessary for normal function of all cells.4  A study 
examining the association between habitual betaine and choline with incident CHD, stroke, 
lung cancer, breast cancer, and colorectal cancer within a large postmenopausal cohort could 
provide numerous public health benefits.  Solely estimating the habitual intake of choline and 
betaine for individuals in the WHI OS provides information with regards to the distribution 
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of intakes in postmenopausal women.  This represents a scientific contribution since there is 
limited population based data on betaine and choline consumption. Currently, only an 
“Adequate Intake” and UL for dietary choline consumption exists, determined by the U.S. 
Institute of Medicine’s Food and Nutrition Board in 1998, using data from liver damage 
prevention studies.23  Examining the association between the range of dietary intakes and the 
aforementioned endpoints extends this body of research to address chronic diseases with a 
heavy population burden.  Since betaine and choline are micronutrients consumed in the diet, 
an individual’s exposure levels to these micronutrients can be modified.  Consequently, any 
betaine/choline – chronic disease associations that are identified will potentially reveal 
modifiable risk factors for the respective disease.  
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CHAPTER II  
SPECIFIC AIMS/ SCIENTIFIC QUESTIONS 
II.1 Specific aims 
Until very recently there were insufficient compositional data to estimate the dietary 
intake of betaine and choline in the general population.  Accordingly, only “Adequate 
Intake” levels have been suggested thus far by the Food and Nutrition Board of the Institute 
of Medicine. Dietary betaine and choline intake may also be associated with incident CHD 
through the homocysteine methylation pathway.  This has been indicated by studies which 
have shown that dietary betaine and choline may be important for lowering plasma 
homocysteine concentrations, through methylation of homocysteine to form methionine, 
even when dietary consumption of folate and other B vitamins is adequate. This doctoral 
research was designed to address gaps in knowledge about the distribution of dietary betaine 
and choline intake and to evaluate the strength of association between dietary betaine and 
choline intake and CHD.  We addressed these questions in extant data on participants of the 
WHI OS (n=93,676) and the WHI DM trial (n=48,835).
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Aims   
• Aim 1 
Chapter IV.1 Paper 1: Describe the distributions of choline and betaine intake in both the 
WHI OS and the WHI DM trial at baseline, based on the WHI Food Frequency 
Questionnaire. 
• Aim 2 
Chapter IV.2 Paper 2: Estimate the systematic error in the measurement of betaine, 
choline, folate, B6 and B12 from the WHI Food Frequency Questionnaire by comparison 
to four-day food records. 
• Aim 3 
Chapter IV.2 Paper 2: Estimate the random error in the measurement of betaine, choline, 
folate, B6 and B12 from the WHI Food Frequency Questionnaire through the one-year 
reliability of the standardized WHI Food Frequency Questionnaire measurements, in a 
sample of the usual diet arm of the DM trial participants. 
• Aim 4 
Chapter IV.3 Paper 3: Estimate the relationship of dietary total choline and betaine 
intake, separately and jointly, with the risk of incident CHD in the WHI OS. 
• Aim 5 
Chapter IV.3 Paper 3: Correct the estimated association of choline and betaine with 
incident CHD for measurement error in the exposure variable(s). 
.  
 
  
CHAPTER III  
STUDY DESIGN AND RESEARCH METHODS 
III.1 Overview 
 
   We estimated the dietary intake of choline and betaine in the OS and DM components 
of the WHI using a semi-quantitative self-administered 122 item WHI FFQ completed at 
study baseline/ enrollment between 1993 and 1998.  We ascertained the variability in the 
WHI FFQ with reference to a four-day food record (FDFR). We estimated the within-person 
repeatability of the WHI FFQ estimates of the methyl donors betaine, choline, methionine, 
folate (food folate and total folate), B12, and B6 in DM Usual Diet arm participants who 
completed a FFQ at both enrollment and at one-year of follow-up. From the within-person 
repeatability data, we constructed a mixed model assessing the joint intra-individual 
variability for all interrelated nutrients. Through a maximum of 12 years of follow-up we 
estimated HRs and 95% confidence intervals for associations using Cox Proportional 
Hazards models and models with a one standard deviation (SD) nutrient density adjusted 
choline, betaine + choline, and he interaction of choline with betaine. Based on the intra-
individual variability for all interrelated nutrients models, we estimated the associations 
between habitual intake of choline and betaine and incident CHD in the WHI corrected for 
reliability. 
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III.2 Design 
III.2.1 Source Population 
The WHI is a large and complex longitudinal clinical investigation into strategies for 
the prevention and control of some of the leading causes of morbidity and mortality among 
postmenopausal women, including cancer, cardiovascular disease, and osteoporotic fractures.  
The WHI was initiated in 1992, currently in a follow-up extension (since September 2006).  
It consists of 161,809 postmenopausal women ages 50 to 79 years-old who enrolled at 40 
clinical centers across the United States into either the OS (n= 93,676) or the clinical trial 
component  (n= 68,133) between October 1, 1993 and December 31, 1998.1  The OS 
component of the WHI was designed to assess new risk indicators and biomarkers for disease 
in a large prospective cohort of postmenopausal women.  The WHI clinical trials comprised 
of three overlapping components, each a randomized controlled comparison among women 
who were postmenopausal and in the age range of 50 to 79 at randomization.  The 
randomized CT of the WHI each individually evaluated hormone therapy, dietary 
modification, and calcium and vitamin D supplementation.  Of the 68,133 clinical trial 
participants, 48,835 (71.7%) took part in the DM trial, in which 19,541 were randomized to 
receive a low-fat diet and 29,294 were randomized to their usual diet.  This study utilized 
data from all women in the OS (n=93,676) and the DM trial (n= 48,835) of the WHI Study.     
III.2.2 Inclusion/ Exclusion Criteria 
Overall, the WHI eligibility criteria were designed to be as broad as reasonably 
possible in order to maximize the generalizability of the study results to the population of 
postmenopausal women.2  The WHI enrolled postmenopausal women aged 50- 70 years of 
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age at baseline.  Women older than 54 years of age must have had no menstrual period for at 
least six months, and those between the aged 50- 54 must have had no menstrual period for at 
least twelve months.  Participants had to be able and willing to provide written informed 
consent, and intended to reside in their local area for at least three years.2   
Participants were excluded from the WHI study if they had medical conditions 
predictive of a survival time of less than 3 years; if they were known to have conditions or 
characteristics inconsistent with study participation and adherence (alcoholism, drug 
dependency, mental illness, dementia); or if they were active participants in another 
randomized controlled clinical trial.2, 3   
For the purposes of this study, we excluded data from participants whose energy 
intake estimates suggest that they did not complete the FFQ in a reasonable manner.  
Specifically, we excluded respondents with FFQ energy estimates of less than 600 or greater 
than 3,500 kcal/day.  These FFQ energy estimate based exclusions were identical to the ones 
used in the DM trial.4 This study also excluded women with prevalent disease for the 
respective study outcome.  Participants were excluded from analyses of cancer if they had 
and if they self-reported a history of any type of cancer except non-melanoma skin cancer, 
and excluded from the analyses of CVD endpoints if they had a history of MI, stroke, angina, 
congestive heart failure, coronary revascularization, or peripheral arterial disease.5    
III.2.3 Racial/ Ethnic Selection 
In the WHI inclusion of women of racial/ethnic minority groups was emphasized, 
with an overall target of 20% in the OS, roughly equal to the proportion of minority women 
ages 50 to 79 as estimated by the 1990 U.S. Census3.  Recruitment of minority women into 
the DM was at target (18.6%) and was somewhat lower in the OS (16.7% n=15,663).3  The 
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frequency of ethnicities within the OS, DM and usual diet arm of the DM are shown in Table 
III.1.  Except for Hispanics, proportional representation of minority groups (Black, American 
Indian, Asian/ Pacific Islander) was close to the national distribution (data not shown).   
 
Table III.1  WHI observational and dietary modification study randomization/ enrollment by 
ethnicity3 
  
Observational 
Study  
Dietary 
Modification 
Trial  
Usual Diet 
Arm (only) 
  n = 93,676  n = 48,835  n = 29,294 
  N %  N %  N % 
 
Race/ ethnicity         
 
American Indian/ 
Alaskan Native 422 0.5  203 0.4  115 0.4 
 
Asian/  
Pacific Islander 2,671 2.9  1,107 2.3  674 2.3 
 Black 7,639 8.2  5,266 10.8  3,129 10.7 
 Hispanic 3,623 3.9  1,854 3.8  1,099 3.8 
 White 78,013 83.3  39,759 81.4  23,890 81.6 
 Unknown 1,308 1.4  646 1.3  387 1.3 
 
III.2.4 Outcome Assessment 
III.2.4.1 Overview 
WHI OS participants were mailed a self-administered medical update questionnaire 
every one year.  If participants did not complete and return the questionnaire in a timely 
manner they were contacted over the phone to obtain the medical update information.  
Participants had WHI clinic visits at baseline, three-year follow-up, and six-year follow-up.  
If outcomes were reported, portions of the medical record including discharge summaries and 
results from relevant diagnostic and lab tests were then requested and assembled and 
provided to the local WHI medical adjudicator who classified the event according to WHI 
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protocol.  Central adjudication was in place for cancer and cardiovascular disease endpoints 
in the CT.   
Central adjudicators from the clinical trial centers did not adjudicate cases from their 
own clinic.  WHI participants lost to follow-up or known to be dead were matched to the 
National Death Index to search for unreported deaths and to ascertain causes of death.6   The 
degree of agreement between locally classified outcomes and centrally adjudicated events in 
the WHI study is presented in  
Table III.2 and can be seen to be high (78-97%).6  The agreement of central review 
with local adjudication in the WHI clinical trials was 91%5 (Not shown in  
Table III.2).  The lowest agreement was seen in cases of in situ breast cancer.  The 
agreement between local and central adjudication for cause of death was very good for both 
cancers and cardiovascular diseases, with the cause of death confirmed in 94% and a related 
cause found in 3%.  The endpoints of interest for Aims 4 and 5 are CHD, stroke, incident 
colorectal, breast, and lung cancer.   
Table III.2  Centrally adjudicated results for locally confirmed outcomes from the Clinical 
Trials and a sample of the Observational Study from Curb et al. 20036 
 Centrally Adjudicated 
 Total Confirmed 
Locally adjudicated outcome N N % 
    
Cancers    
 Breast 332 320 96 
       Invasive 258 237 92 
       In situ 74 58 78 
 Colorectal 101 95 94 
 Endometrial 67 63 94 
 Ovarian 36 32 89 
    
Cardiovascular    
 MI 403 351 87 
 Angina 911 738 81 
 Congestive heart failure 396 313 79 
 CABG/PTCA 748 727 97 
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 Deep vein thrombosis   70   66 94 
  Pulmonary embolism   36   34 94 
III.2.4.2 Cardiovascular Disease 
We assessed incident CHD which consisted of clinical myocardial infarction (MI) 
requiring overnight hospitalization, coronary revascularization and CHD death.   
 
Myocardial Infarction 
 
The WHI algorithm for classifying hospitalized MI includes elements of the medical 
history, all ECG readings from the respective hospitalization, and results of cardiac 
enzyme/troponin determinations, which is adapted from standardized criteria.7, 8  Cardiac 
enzyme and/or troponin levels were classified as normal, equivocal (greater than the upper 
limit of normal (ULN) but less than twice the upper limit of normal ULN), abnormal (greater 
than or equal to twice the ULN) or incomplete, based on the normal range at the 
corresponding hospital.6  The most abnormal results of all enzyme determinations were used 
in the classification of events.  MI events that occurred during surgery or were aborted by 
thrombolytic therapy or procedures are also included.  Aborted MIs were symptomatic 
episodes with ECG evidence of acute MI and normal cardiac enzymes (lower than the ULN) 
where the ECG changes are resolved with therapy.  The algorithm presented in Table III.3 
details the categorization of MI events as “definite”, “probable”, or “not an MI”6.  This 
analysis considered both definite and probable MI events as MI endpoints.  
 
 
Coronary Heart Disease Death 
 
CHD death was defined as death consistent with CHD as the underlying cause plus one 
or more of the following: preterminal hospitalization with MI within 28 days of death; 
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previous angina or MI and no potentially lethal non-coronary disease process; death resulting 
from a procedure related to coronary artery disease; or death certificate consistent with CHD 
as the underlying cause.6  Evidence from recent hospitalization and autopsy records was 
considered the most reliable source for determining cause of death.  Cause of death 
determinations were based solely on death certificate diagnosis only when no other records 
were available.  CHD death was further sub-classified within the WHI study as: 
• Definite fatal MI: No known non-atherosclerotic cause and definite MI within 4 weeks 
prior to death.  
• Definite fatal CHD: No known non-atherosclerotic cause and at least one of the 
following: chest pain within 72 hours of death or a history of chronic ischemic heart 
disease in the absence of valvular heart disease or non-ischemic cardiomyopathy. 
• Possible fatal CHD: No known non-atherosclerotic cause and death certificate consistent 
with CHD as underlying cause.  
Coronary disease deaths were subclassified as definite or possible, depending upon the level 
of evidence.  These analyses included all sub-classifications of CHD death as events.  
 
Coronary revascularization 
The WHI study defined coronary revascularization as any documented coronary 
artery bypass graft surgery or, percutaneous transluminal coronary angioplasty, coronary 
stent, or coronary atherectomy.  Both in-patient and out-patient percutaneous coronary 
interventions were included as events. 
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Table III.3  Criteria for the classification of myocardial infarction from Curb et al. 20036 
 
  Cardiac Enzymes/Troponin  
ECG Pattern/Symptoms  Abnormala  Equivocalb Incomplete Normal 
Cardiac pain present      
   Evolving Q wave and evolving ST-T abnormalities  Definite  Definite  Definite  Definite  
   Equivocal Q wave evolution; or evolving ST-T abnormalities, or new left bundle branch block  Definite  Definite  Probable  No MI  
   Q waves or ST-T abnormalities suggestive of an MI and not classified above  Definite  Probable  No MI  No MI  
   Other ECG, ECG absent or uncodable  Definite  No MI  No MI  No MI  
Cardiac Pain absent      
   Evolving Q wave and evolving ST-T abnormalities  Definite  Definite  Definite  Probable  
   Equivocal Q wave evolution; or evolving ST-T abnormalities; or new left bundle branch block  Definite  Probable  No MI  No MI  
   Q waves or ST-T abnormalities suggestive of an MI and not classified above  Probable  No MI  No MI  No MI  
   Other ECG, ECG absent or uncodable  No MI  No MI  No MI  No MI  
aMore than twice the upper limit of normal at the corresponding hospital laboratory. When multiple enzyme determinations are available, the most abnormal 
results are used in classifying the event. 
bGreater than the upper limit of normal, but less than twice the upper limit of normal at the corresponding hospital laboratory. 
ECG = electrocardiogram, MI = myocardial infarction 
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III.2.5 Main Exposure Assessment 
Zeisel and colleagues analyzed betaine and choline concentrations in over 300 
common foods under the USDA National Food and Nutrition Analysis Program.9, 10  
Building on this developmental work estimated the dietary intake of choline and betaine in 
approximately 142,500 participants in the WHI OS and DM Trial, for whom baseline FFQ 
dietary intake assessments are available as well as in the 48,835 DM trial participants, for 
whom WHI FFQs were collected at one year and within a subsample (n=2,245) where FDFR 
assessments were collected at one year.11-13   These dietary assessment data, edited and 
processed by WHI nutrition staff, were available as electronic records at the WHI Clinical 
Coordinating Center (CCC).  We converted food item data into estimates of total daily intake 
of choline and betaine using the food concentration data published by the USDA9, which 
were integrated into the Nutrition Data System for Research (NDS-R) 2007.  At that same 
time we estimated values for the possible covariates of folate, B6 and B12 using the same 
system.  The specific uses of the FDFR, WHI baseline and one year FFQ for the completion 
of study aims is detailed within the subsequent sections III.2.5.1 WHI FFQ and III.2.5.2 
Four-Day Food Record and displayed in Table III.4. 
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Table III.4  Dietary assessment data from each Women’s Health Initiative Study component 
required to address study aims 
 
FFQ= Food Frequency Questionnaire 
UD = Usual Diet Arm of Dietary Modification Trial 
LFD= Low-fat Diet Arm of Dietary Modification Trial 
OS= Observational Study 
 
III.2.5.1 WHI FFQ 
Food and nutrient intake were assessed by a semi-quantitative self-administered FFQ, 
based on instruments previously used in the Women’s Health Trial Vanguard 14 and Full 
Scale Studies 15, the Working Well Trial16, and the Women’s Health Trial Feasibility Study 
in Minority Populations.17 The FFQ was divided into three sections: adjustment questions, 
foods and food groups, and summary questions18.   The nineteen adjustment questions allow 
more refined analysis of fat and fiber intake, and it is also used in the analysis software to 
calculate the nutrient content of specific food items.4, 18  These questions include seven items 
contained the original National Cancer Institute/ Block FFQ4. The main section, food line 
items, consists of 122 foods or food groups, with questions on the usual frequency of intake 
and portion size questions on usual frequency of intake18.  Food items were added to 
incorporate regional and ethnic foods in the United States.4, 18 The four summary questions 
ask about the usual intake of fruits, vegetables, and fats added to foods or in cooking. It has 
been shown that these questions can reduce the bias toward over-reporting of total food 
       
Aims 
Addressed   Baseline FFQ   One Year FFQ   
Four-Day Food 
Record at One 
Year 
       
1  OS, LFD, UD     
2    UD, LFD  UD, LFD 
3  UD  UD   
4  OS     
5  OS, LFD, UD  UD, LFD  UD, LFD 
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consumption when there are long lists within food groups.19 The time reference for all 
questions was “in the last 3 months”18. Frequency of food item consumption were listed as 
categories including: “never”, “once a month or less”, “2-3 times per month”, “1 per week”, 
“2 per week”, “3-4 per week”, “5-6 per week”, “1 per day”, and  “2+ per day”.  Serving size 
amounts were listed as small, medium, and large.  Reference amounts were listed for medium 
serving sizes for each food type; small servings were defined as less than or equal to one-half 
the medium serving size and large servings were greater than or equal to one-and-a-half 
times the medium serving size. The FFQ completion instructions were self-instructive, 
provided as printed directions and examples on the questionnaire itself and an additional 
page with portion size pictures on one side and instructions on the other side.4   
The WHI FFQ was administered in the OS and DM to measure the usual frequency of 
intake of foods and portion sizes.  Using the portion size information, the frequency of 
consumption, and the nutrient values assigned, estimated choline, betaine folate, B6 and, B12 
intake will be calculated for individuals who participated in the WHI OS and DM.  Nutrient 
intake values exclude nutrients from supplements. The WHI CCC assigned these values to 
the WHI FFQ food items in both the OS n=93,676 and the DM (n=48,835) by re-processing 
the records with the NDS-R 2007.  These new nutrient values were merged with the existing 
database and dietary total choline and betaine intake values based on the FFQ completed at 
baseline were used to address Aim 1 (approximately 142,500 participants).  Since the DM 
trial had more stringent exclusion criteria (baseline diet with fat intake of > 32% of total 
calories consumed; prior cancers in last 10 years; anyone with adherence concerns; etc)20 
than the OS, only the OS were used to examine the association of habitual dietary choline 
and betaine intake with incident CHD to address Aims 4 and 5.   
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As mentioned in Section III.2.5 Main Exposure Assessment, the DM participants 
completed a WHI FFQ at baseline and one year follow-up.  Because the low-fat diet arm of 
the DM received a dietary intervention, random error was estimated only in the usual diet 
arm of the DM trial.  We compared the baseline FFQ to the FFQ administered at one year 
within the DM usual diet arm to assess random error, thus addressing Aim 3.  We also 
estimated the random error in the measurement of betaine, choline, folate, B6 and B12 from 
the WHI FFQ through assessing the one-year reliability of the WHI FFQ measurements (Aim 
3).     
A dietary assessment study was carried out to assess the measurement characteristics 
of the WHI FFQ by Patterson et al.4  The reliability of the WHI FFQ for estimating 30 
nutrients and micronutrients was estimated by having 113 participants complete a FFQ 
before and soon after their first clinic visit.  After the second clinic visit, the participants were 
mailed a second FFQ for completion.  Between the first and second clinic visits, participants 
completed four dietary recalls.  After the second clinic visit, participants kept a FDFR that 
was collected at the third and final screening visit.  Agreement between the two FFQs was 
quantified using intraclass correlation coefficients.  The 30 nutrients examined in the study 
did not include betaine or total choline.  The sample in the Patterson et al. study consisted of 
women who were screened for participation in the WHI study in 1995 where each of the 16 
Vanguard Clinical Centers enrolled about 10 women (5 women with diets less than 32% 
energy from fat and 5 with diets greater than or equal to 32% energy from fat).4  As 
described by Patterson et al., the test-retest reliability of the nutrient intake estimates from the 
repeat FFQ’s was high.  The intraclass correlation coefficients ranged from 0.67 (retinol, 
73 
vitamin C, and B12) to 0.82 (fiber), 0.84 (magnesium), and 0.92 (alcohol).  The mean of all 
correlation coefficients was 0.76.     
 
III.2.5.2 Four-Day Food Record 
A sub-sample of women, in the DM (n=2,245), completed a FDFR at one year13.  The 
FDFR was kept on four alternate days, insuring that one day was a Saturday or Sunday.  
Participants received instructions on how to keep an accurate food record including: a 
booklet; a 15- minute videotape; 15–30 minutes of additional instruction from study-certified 
clinical staff 4.  Participants mailed completed records to the WHI CCC, where staff reviewed 
them and contacted participants if there were incomplete food descriptions or missing portion 
sizes. Records were then entered into the NDS-R.4     
The FDFR information was re-analyzed at the WHI CCC, using the newest version of 
NDS-R 2007. These data were used by us to estimate the systematic error in the 
measurement of betaine, total choline, folate, B6 and B12 from the WHI FFQ.  These new 
nutrient summary values were then compared to values estimated by the WHI FFQ at one 
year to address Aim 2.   
In the same Patterson et al. study detailed above, a dietary assessment study was 
carried out to assess the measurement characteristics of the WHI FFQ as compared to 
corresponding estimates from a FDFR and four twenty-four hour food recalls.4  Since it was 
based on a smaller population (n=113) and the 30 nutrients examined in the study did not 
include betaine and total choline.  WHI FFQ nutrient estimates were on average slightly 
lower than those from the dietary recalls and records4.  For 21 of the 30 nutrients, mean 
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intake estimated by the FFQ were within 10% of those estimated by the food record and for 
the 22 of the 30 nutrients the FFQ was within 10% of those values from the food recall.4  
Table III.5  Pearson correlation coefficients between selected nutrient intakes estimated by a 
food frequency questionnaire and 8 days of dietary intake* in the Women’s Health Initiative 
Dietary Assessment Study (N=113), From Patterson et al. 19994 
Nutrient Unadjusted Energy-adjusted 
Energy, Kcal 0.37 --- 
Fat, percentage of energy 0.62 --- 
Total fat 0.49 0.58 
 Saturated fat 0.44 0.56 
 Polyunsaturated fat 0.47 0.44 
 Monounsaturated fat 0.52 0.57 
Alcohol 0.86 0.86 
Vitamin B6 0.50 0.57 
Vitamin B12 0.18 0.18 
Folate 0.52 0.52 
        
*Four twenty-four-hour recalls and a four-day food record 
III.3 Data Analysis Overview 
 Variables from the WHI most pertinent to this study are listed in Table III.6.  We 
described the energy-adjusted choline, betaine, and choline + betaine distributions of the 
participants in the WHI OS, by demographic and baseline characteristics. The nutrient 
density adjusted values for choline, betaine and choline + betaine were analyzed as both 
continuous variables and as quantiles.  In light of the recognized metabolic relationship 
between choline and betaine described in Figure I.2, we examined the associations of choline 
alone, choline + betaine, and the interaction of choline with betaine 21 with the risk of 
incident CHD.  The age- and multivariable-adjusted associations, with 95% CIs, between the 
incidence of CHD in relation to the nutrient density adjusted choline alone, choline + betaine, 
and the interaction of choline with betaine were estimated using Cox proportional hazard 
regression models 22 using SAS Version 9.3 (SAS Institute Inc., Cary, NC). The parameter 
point estimates of choline alone, choline + betaine, the interaction of choline with betaine, 
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alcohol intake, folate, B6 and B12 were corrected using the Prentice method 23 and variance 
estimates were corrected using the estimator of Rosner et al. 24 Additionally, this study 
estimated the within-person variability associated with the FFQ, administered at baseline and 
one year follow-up, through the calculation of reliability (See Section III.3.5 Reliability). 
 Recognizing the metabolic relation between choline and betaine and the methyl-
exchange relation between choline and folate, 34, 35 we modeled each of these interactions in 
separate models.  Interaction p-values < 0.20 were considered significant.    
III.3.5 ReliabilityBecause of the implementation of folic acid fortification in 1996 
(mandated 1998), we used different folate food content values depending upon when the 
dietary assessments were performed.25 
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Table III.6  Variables of interest from the Women's Health Initiative database 
Variable Variable Type 
Age at Enrollment Continuous 
Body Mass Index Ordinal Categorical 
Waist/ Hip Ratio Continuous 
Physical Activity Categorical 
Study Center Categorical 
Cigarette smoking  Categorical (Never/ past/ current smoker) 
Dietary Betaine Continuous 
Dietary Choline Continuous 
Dietary Folate Continuous 
Dietary Total Energy Continuous 
Race Categorical 
Years of Education Categorical 
Income Categorical 
Region of the United States Categorical 
Vitamin supplement intake/use- Folic acid, B12,and B6 Dichotomous (Yes/No) 
Alcohol intake Categorical 
Post-menopausal Hormone Use Ever Dichotomous (Yes/No) 
Relatives had stroke Dichotomous (Yes/No) 
Relatives had heart attack Dichotomous (Yes/No) 
Relatives lung cancer ever Dichotomous (Yes/No) 
Relatives colon-rectal cancer ever Categorical-Dichotomous (Yes/No) 
Relatives breast cancer ever Categorical-Dichotomous (Yes/No) 
Relatives cancer ever Categorical-Dichotomous (Yes/No) 
Age at first period Continuous 
Age at last regular period Continuous 
Bilateral oophorectomy Categorical-Dichotomous (Yes/No) 
Participant's age at first child's birth Categorical-Dichotomous (Yes/No) 
Number of term pregnancies Continuous 
Number of children breastfed Continuous 
Mammogram screening frequency Categorical 
Diabetes Dichotomous (Yes/No) 
History of hypertension Dichotomous (Yes/No) 
Dietary Cholesterol 
 
 
 
 
 
Continuous 
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III.3.1 Adjustment for Total Energy Intake 
When analyzing the dietary macro- and micro- nutrients, the total energy intake of the 
participant was considered.  Differences in the amount of total energy intake between persons 
can be attributed to three different factors: physical activity; body size; and metabolic 
activity.26, 27 Through its components, total energy intake is a risk factor for each of the 
chronic disease endpoints in this study.  In order to determine whether the macro- and micro-
nutrients affect the risk of disease via a pathway other than energy production, energy intake 
must be adjusted for.28 Total energy adjusted values were to be computed as the residuals 
from a linear, least-squares regression model regression model with total caloric intake as the 
independent variable and the respective absolute micronutrient intake as the dependent 
variable.26, 27  Adjusting for total energy intake using the residual method, obtaining 
micronutrient residuals, would provide measures of nutrient intakes that are uncorrelated 
with total energy intake.26, 29  However in the final analysis, the effect of total energy was 
examined using a nutrient density approach, where dietary B vitamin intake was examined 
using nutrient densities (units of nutrient/kilocalorie).29, 30  While macronutrients provide 
energy in bulk, most micronutrients are not highly correlated with energy intake, fueling a 
debate whether total energy adjustment should be done at all for micronutrient analysis28.  
Since this issue is still under some debate28, this study will analyze micronutrients with and 
without adjustment for total energy intake.  There are possible secondary benefits to the 
above mentioned and disputed benefits of total energy intake adjustment for micronutrients 
consumption.  This approach has been shown, in some instances, to reduce extraneous 
between-person variation due to general over- or under- reporting of intake.27 
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III.3.2 Survival Analysis 
The age- and multivariable-adjusted associations, with 95% CIs, between the 
incidence of CHD in relation to nutrient density choline, betaine, and choline + betaine were 
estimated using Cox proportional hazard regression models.22 The time scale for all analysis 
was person-time in study.  The participants accrue time beginning with their enrollment date.  
Participant’s follow-up time ended if they died, experienced the endpoint for the incident 
CHD endpoint, or if they could no longer be contacted for follow-up.  Individuals who were 
lost to follow-up or were event-free throughout the follow-up period were considered 
censored. Verification of the proportional hazards assumption was performed using plots of 
the log (-log) survival curves and using Cox test for continuous time interaction.31 
III.3.3 Assessment of Confounding 
Variables possibly confounding the relationships of choline and betaine intake with 
incident CHD was assessed with a directed acyclic graph (DAG).32  The DAG was 
constructed based upon subject matter knowledge.  The prototypical DAG was constructed 
based upon subject matter knowledge (Figure III.1).  We considered hypertension, physical 
activity, body size, dietary fat intake, type 2 diabetes, cigarette smoking, alcohol intake, 
postmenopausal hormone therapy, as possible confounders of the association of betaine and 
choline with the CHD outcome. A covariate was retained if its removal from the fully-
adjusted model changed the parameter point estimate more than 10%. 31, 33  
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Figure III.1   Prototypical directed acyclic graph of the association between habitual betaine/ 
choline dietary intake and coronary heart disease 
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III.3.4 Assessment of Modification 
 Recognizing the metabolic relation between choline and betaine and the methyl-
exchange relation between choline and folate, 34, 35 we modeled each of these interactions in 
separate models.  Interaction p-values < 0.20 were considered significant.    
III.3.5 Reliability 
It is thought that dietary intake levels based on an FFQ are positively correlated with 
the true usual intake, but involve both random and systematic bias.36-40  Using the WHI FFQ 
baseline and one year follow-up data from the DM usual diet arm alone, this study addressed 
Aim 3 assessing the within-person random error of the WHI FFQ.  The one year interval 
between WHI FFQs can possibly avoid conditions associated with shorter repeat intervals 
where participants may simply tend to remember and enter their previous responses.41  While 
it is possible that both true dietary intake changes and errors in measurement (performance of 
the questionnaire) both contribute to measures of reproducibility, both sources of variation 
actually do contribute to misclassification of dietary intakes41.  Nonetheless, the variability 
associated with a one-year interval between completions of the WHI FFQs should mainly 
reflect variation associated with completing the questionnaire.41  
Thus, the working assumption was that the usual diet between the two WHI FFQ 
evaluations (across one year) was relatively stable and the systematic dietary assessment 
error was mainly non-differential.  These repeated measurements therefore permitted the 
estimation of the reliability.  The replicate measures were used to separate the within- and 
between- person components of variation.  We used mixed effects models to partition the 
measurement error into components. With these estimates, reliability coefficients, ρ, were 
calculated as the proportion of total variance attributable to the between-person component. 
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The reliability coefficient can also be interpreted as the correlation between different 
measures on the same individual, where the measures are made at different visits.42 
Linear mixed-effects models were used to estimate the various components of total 
variation in the dietary data. We partitioned the total variance (σT2) into between-pair (σBP2) 
and intra-individual (σe2) variance components by treating paired FFQ measurements as 
random effects in linear mixed-effects models. The proportion of the total variance 
attributable to between-person variability, or the reliability coefficient (R = σBP2 / σT2), was 
interpreted as the correlation between paired measurements. We obtained separate reliability 
coefficients for betaine, choline, methionine, total folate (DFE), natural folate, B12, and B6. 
We also calculated reliability coefficients in models when all of the micronutrients were 
considered simultaneously.  The coefficient of variation (CV) was used to express the 
standard deviation as a percentage of the mean, calculated as the square root of the within-
pair variance component divided by the mean of the paired observations, multiplied by 100. 
The following benchmarks were used for characterizing the reliability of the intake 
measurements: slight reliability, 0.00-0.20; fair reliability, 0.21-0.40; moderate reliability, 
0.41-0.60; substantial reliability, 0.61-0.80; almost perfect reliability, 0.81-1.00.35 Bland-
Altman plots were used to characterize the degree of disagreement between the baseline and 
one-year subsequent FFQ measures and to identify outliers and trends.30 
 Measurement error estimates of nutrient intake was accounted for in the estimation 
of their association with incident CHD using an algorithm described by Chambless and Davis 
to correct for bias caused by measurement error in independent variables.43  A bootstrapping 
procedure was used to estimate the confidence intervals of the regression coefficients 
obtained in the regression models. 
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III.3.6 Validity Analysis 
As previously mentioned, there are important considerations to be made with respect 
to the measurement characteristics of the FFQ (See Sections I.2.3.5 Food Frequency Q and  
I.2.3.6 Measurement Error).  Since the FFQ does not specifically note all foods consumed in 
the diet and exact quantities, it is crucial to examine the degree to which the FFQ can 
measure “true” dietary choline and betaine intake.41  This study attempted to quantify the 
amount of measurement error attributable to the validity of the FFQ.    It has been argued that 
when examining the validity of the FFQ, diet records are likely to have the least correlated 
errors of all the available and feasible comparison methods.41   The errors are less correlated 
since the diet record is open-ended, does not depend on memory, and allows for direct 
measurement of portion sizes.42  We investigated the measurement characteristics of the WHI 
FFQ as compared to the FDFR, a short-term dietary recording method.  In the DM, a sub-
sample of women completed a FDFR at one year and had their data entered into the NDS-R 
(n=2,245).13  For these participants, the FDFR information and the WHI FFQ, also completed 
at one year, were re-analyzed at the WHI CCC, using the newest version of NDS-R 2007. 
This data was used to estimate the systematic error in the measurement of betaine; total 
choline; folate; B6; B12 from the WHI FFQ, thus addressing Aim 2.   
We also sought to determine the concordance between baseline estimates of dietary 
betaine, choline, methionine, natural folate, total folate, B12, and B6 from the WHI FFQ with 
those from the FDFR for DM study participants. For this we used Pearson product-moment 
correlations to quantify the degree of linear association between food and nutrient intake 
estimates measured by the FFQ with those measured by the FDFR. Linear regression models 
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were fitted using FDFR and FFQ nutrient intakes estimates.44 The resulting regression lines 
were plotted against scatter plots of the actual data. 
III.4 Statistical Power   
The minimum detectable HR for the analysis of the relationship between incident 
CHD and nutrient density quartiles of choline, betaine, and choline + betaine were estimated 
for the WHI OS cohort.  We conservatively evaluated study power by calculating the effect 
size that could be detected using the number of WHI OS events as of September 12, 2005, 
7.58 mean years of follow-up, accrual period of 4.33 years, with an α = 0.05 and power set at 
80% and 90% (Table III.7).45-47  For the purposes of these calculations we assumed that the 
choline and betaine exposures are grouped in quartiles.  Quartile 4 was considered the 
referent group and we assumed that it had the same event rate as the entire WHI OS cohort.  
nQuery advisor 5.0 software (Statistical Solutions, Saugus, MA) was used as the 
computational tool.  The values in Table III.7 represent the minimum detectable HR’s and 
corresponding power for any given comparison between Quartile 4 and each of the other 
quartiles.  
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Table III.7  Minimum detectable hazard ratios given 80% and 90% power and α = 0.05, 
when examining the hazard of cancer outcomes by energy-adjusted quartiles of choline, 
betaine, and choline + betaine, in the WHI observational study. 
Disease endpoint 
Number of events 
(%) 
Minimum 
detectable 
hazard ratio 
Power 
    
Coronary Heart Disease 2,471 (2.64 ) 1.16 0.80 
  1.19 0.90 
    
Clinical Myocardial Infarction 1,898 (2.02) 1.19 0.80 
  1.22 0.90 
    
CHD Death 824 (0.88) 1.30 0.80 
  1.35 0.90 
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CHAPTER IV  
RESULTS 
  
IV.1 Estimation of the dietary intakes of choline and betaine intake in the Women’s 
Health Initiative 
 
Introduction   
Dietary choline, an essential micronutrient which is involved in the methylation of 
homocysteine to form methionine, 1-4 directly affects cholinergic neurotransmission 5-8 and 
lipid transport from the liver.9-12  Although many foods contain choline13 (e.g. red meat, 
chicken, liver, eggs, soybeans, and wheat germ14), there is substantial variability of intake, as 
the highest reported dietary intakes of choline in humans are at least double that of the 
lowest.15-18  Betaine, a choline derivative, is a donor of methyl groups to homocysteine to 
form methionine.  Betaine is found in the diet (e.g. dark and white bread; spinach; pasta)18 
and it can be endogenously synthesized from choline.19   
Choline and betaine depletion are associated with several adverse health outcomes.20, 
21 Choline depletion can affect health status, as it is a micronutrient that is essential for 
normal function of all cells.9  Betaine and choline deficiencies have been associated with 
reduced capacity for handling methionine load, resulting in elevated homocysteine,22 a risk 
factor for cardiovascular disease.23   Dietary choline and betaine deficiencies also promote 
DNA hypomethylation through decreased S-adenosylmethionine concentrations and 
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associations of DNA hypomethylation with colorectal,24 breast,25 and lung cancers26, 27 have 
been reported.  An adequate intake (AI) for choline of 550 mg/day for men and 425 mg/day 
for women was established by the Food and Nutrition Board of the Institute of Medicine of 
the National Academy of Sciences in 1998.28  
Information to estimate choline and betaine intake from common foods in populations 
was insufficient until the recent development of the USDA Special Interest database for 
choline and betaine in foods.13, 14 Since then, four large cohort studies have examined the 
relation between habitual dietary choline and betaine intake (estimated with different 
variations of the FFQ), and incident coronary heart disease,18 cardiovascular disease risk 
factors,17 and distal colorectal adenoma.29  Of note, the previous studies were performed in 
predominantly Caucasian populations with limited geographic variation and likely limited 
heterogeneity in intake.  Our objective is to complement this information by estimating the 
dietary intake of choline and betaine in the Women’s Health Initiative (WHI), an apparently 
healthy, large population of postmenopausal women from diverse racial/ethnic and 
geographic backgrounds across the United States.   
 
Methods 
Study Population 
 This study utilized data collected from the Observational Study (OS) and Dietary 
Modification (DM) Trial components of the WHI, as a WHI FFQ was administered at 
baseline in both studies.  Recruitment of postmenopausal women aged 50 to 79 years who 
were interested in one or more components of the clinical trials was conducted by 40 clinical 
centers throughout the United States between October 1, 1993 and December 31, 1998.  
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Potential participants were excluded if they did not plan to reside in the area for at least three 
years, had medical conditions predictive of survival less than three years, or had 
complicating conditions such as alcoholism, drug dependency or dementia. All participants 
provided informed consent using materials approved by institutional review boards at each 
center. The scientific rationale, eligibility requirements, recruitment methods and other 
aspects of the design of the WHI have been previously described.30-32  A brief description of 
each follows. 
 
Observational Study (OS). Participants were enrolled in the OS if they expressed an interest 
in either the DM or hormone therapy (HT) components of the clinical trial, but were 
ineligible or unwilling to participate in the clinical trial component to which they were 
assigned, or if they responded to a direct invitation from the WHI to be screened for 
enrollment into the OS. Thus, the specific exclusions for the DM and HT components 
influenced the characteristics of women in the OS. 
 
Dietary Modification Trial (DM). Eligibility criteria for the DM trial included willingness to 
be randomized to an intervention or comparison group and having a fat intake at baseline that 
accounted for 32% or more of total caloric intake as estimated based on the WHI food 
frequency questionnaire.33  The most common exclusions included any prior colorectal 
cancer or breast cancer, other cancers except nonmelanoma skin cancer in the previous 10 
years, type 1 diabetes, medical conditions with predicted survival of less than three years, or 
adherence concerns, including having meals frequently prepared away from home. Between 
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1993 and 1998, 48,835 eligible women were randomly assigned to the intervention or a 
comparison group in a ratio of 2:3. 
 
Dietary Assessment 
Food and nutrient intake were assessed by a semi-quantitative self-administered 122 
item FFQ, based on instruments previously used in the Women’s Health Trial Vanguard 34 
and Full Scale Studies,35 the Working Well Trial,36 and the Women’s Health Trial Feasibility 
Study in Minority Populations.37  At enrollment, all participants completed an FFQ designed 
specifically for the study and its measurement characteristics are reported elsewhere.33 
Participants with total energy values outside of  >6000 kcal or  < 600 kcal were excluded 
because values outside these limits are not considered biologically plausible.38 
The WHI Clinical Coordinating Center (CCC) converted food item data into estimates of 
total daily intake of choline and betaine using the Nutrition Data System for Research 
software version (NDS-R) 2007 which utilizes USDA Standard Reference 19,39 developed by 
the Nutrition Coordinating Center, University of Minnesota, Minneapolis, MN.40  The NDSR 
is a windows based dietary analysis program designed for the collection and analyses of 
dietary data. The WHI CCC developed a custom software program that passes the scanned 
data from the FFQ through the nutrient database to yield per person per day estimates of over 
140 nutrients. 
 
Statistical Analysis 
Since the WHI study utilized 40 clinical centers throughout the United States, we 
examined the distribution of betaine and choline for possible regional (Northeast, South, 
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West, Midwest) variation through a comparison of ranks using Kruskal–Wallis one-way 
analysis of variance test.  The four regional categories were based on the US Census 
definition.  The Kruskal-Wallis test was also used to examine variation in mean daily betaine 
and choline between the OS and CT groups. Betaine and choline intakes are presented as the 
mean, median, standard deviation, IQR, mean Wilcoxon Scores for each group.   
Finally, FFQ-derived mean intakes of choline and betaine have been reported by four 
other large cohort studies: the Atherosclerosis Risk in Communities (ARIC) Study,18 the 
Dutch Contribution to the European Prospective Investigation in Cancer and Nutrition 
(PROSPECT-EPIC),17 Framingham Offspring Study,41 and The Nurses’ Health Study 
(NHS).29   The findings from this study are presented along with the data from the other four 
studies.  Analyses were conducted using Statistical Analysis Systems statistical software 
package version 9.2 (SAS Institute, Cary, NC, USA). 
 
Results 
 The original combined study size of both the OS and DM included 142,511 
postmenopausal women.  After excluding WHI participants who had missing dietary 
information for estimated baseline choline or betaine (n = 245), or reported implausible daily 
caloric intake values (< 600 kcal/day n = 3,340 and > 5000 kcal/day n =314) these analyses 
were based on 138,612 observations (48,603 DM and 90,009 OS).  Among the 138,612 
ethnically diverse cohort of women (16.5% minority), the mean (SD) age was 63.1 (7.2) 
years and roughly three quarters were overweight or obese (BMI ≥ 25 kg/m2) (Table IV.1.1).   
Spearman correlations between the interrelated nutrients choline, natural folate, and 
methionine were 0.93 for choline-methionine, and 0.74 for choline-natural folate.  The 
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distributions of both choline and betaine intakes were right skewed (skewness: 1.3 and 1.4, 
respectively) and had excess peakedness (kurtosis: 3.6 and 3.7, respectively).  The 
distributions of reported dietary choline and betaine did not differ substantially between the 
restricted, individuals with plausible total energy values (600 kcal to 6000 kcal), and 
unrestricted population (results not shown).  The overall median daily choline and betaine 
intakes and corresponding IQRs were 264 mg/day (IQR: 201− 341 mg/day) and 164 mg/day 
(IQR: 114− 230 mg/day).  Only 14,313 (10%) of the population met the AI of 425 mg/day. 
The median daily intakes and IQR of choline was 268 mg/day (IQR: 206− 342 mg/day) in 
Whites, 242 mg/day (IQR: 174− 331 mg/day) in Blacks, 250 mg/day (IQR: 181− 342 
mg/day) in Hispanic/Latinos and 233 mg/day (IQR: 174− 312 mg/day) in Asian or Pacific 
Islanders (Figure IV.1.1A).  The proportions of the racial/ ethnic groups meeting the AI were 
10% in Whites, 12%, in Blacks, 13% in Hispanic/Latinos and 9% in Asian Pacific Islanders.  
For betaine, the median daily intakes and IQRs were 166 mg/day (IQR: 117− 231 mg/day) in 
Whites, 164 mg/day (IQR: 112− 245 mg/day) in Blacks, 123 mg/day in (IQR: 78− 184 
mg/day) Hispanic/Latinos and 150 mg/day (IQR: 102− 216 mg/day) in Asian or Pacific 
Islanders (Figure IV.1.1B).    
The estimated choline and betaine intakes are presented by region of the United 
States, based on the US Census definitions (Northeast, South, Midwest, and West) in Figure 
IV.1.2.  The highest median daily intake of dietary choline was seen in the Midwest (278 
mg), followed by the Northeast (264 mg); South (260 mg); West (258 mg) (Figure IV.1.2A).  
Differences by region were also seen for dietary betaine intake (Kruskal-Wallis Test p < 
0.0001) with the lowest median daily betaine intake being the West  (152 mg), followed by 
the Midwest (167 mg); South (169 mg); Northeast (172 mg) (Figure IV.1.2B).   
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The WHI FFQ was completed at study enrollment,33 which took place throughout the 
calendar year across the United States.  Possible seasonal variation in the dietary intake of 
choline and betaine is graphically explored by the geographic location of the study 
participant (West; South; Midwest; Northeast) in Figures IV.1.3 and IV.1.4, which display 
choline and betaine intake by month in which the FFQ was completed.   Only small variation 
by month in which the FFQ was completed was observed, within regions.  The contribution 
of each region towards the total FFQs completed each month were 22-27% for Northeast; 23-
29% South; 18-24% for Midwest; 26-32% for West.  The contribution of each race/ethnicity 
towards the total FFQs completed each month were 82-84% for Whites; 8-10% Blacks; 3-4% 
for Hispanic/ Latino; 2-3% for Asian or Pacific Islander. 
The food items contributing most towards dietary intake of choline and betaine are 
listed in Tables IV.1.2- IV.1.4 for the total population, by region and by race/ethnicity.  
Despite statistically significant differences of choline intake by region, the top four choline-
contributing food items (milk, eggs, chicken, and steak) were the same for each region and 
race/ethnicity save for Asian or Pacific Islanders who consumed a substantial amount of 
choline from rice as well.   The top five betaine-contributing food items (bread, cooked 
greens, cold cereal, spaghetti, and biscuits) were similarly homogenous in their distribution 
across these categories.  The top four choline and five betaine items account for about 34% 
and 80.3% of the respective average micronutrient intakes in individuals (Table IV.1.2). 
While the items observed to contribute most towards dietary choline and betaine intake were 
similar, there was some variation in the amount of each item consumed (mg/day) by region 
and race/ethnicity.  
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Mean intake of choline and betaine derived from FFQ has been reported by four other 
large cohort studies: the ARIC Study, the Dutch Contribution to PROSPECT-EPIC, 
Framingham Offspring Study41, and the NHS.   The findings from these four studies and our 
results from the WHI FFQ are presented in Table IV.5.  NHS and Framingham Offspring 
only presented energy-adjusted betaine and choline values.  The WHI had the lowest mean 
dietary choline values, ARIC and PROSPECT-EPIC were intermediate, and the Framingham 
Offspring and NHS were highest.  Mean dietary betaine was highest in PROSPECT-EPIC, 
intermediate in Framingham Offspring, NHS, and WHI, and considerably lower in ARIC.  
 
Discussion 
 
 In this first study among postmenopausal women (50-79 years of age), the dietary 
intake of choline and betaine estimated from a 122 item FFQ, supplemented with ethnic food 
items, is similar to that reported by previous, more homogeneous studies in different locales. 
The estimated population dietary choline values are lower than the 1998 AI established by 
the Food and Nutrition Board of the Institute of Medicine of the National Academy of 
Sciences. There is modest variability in the dietary intake of betaine and choline by U.S. 
geographic region.  Although seasonal variability in the intake of choline and betaine can be 
detected, the magnitude of these variations is small. 
 There is modest variability in the dietary intake of betaine and choline by self-
identified race/ ethnicity. Notably lower betaine and choline intake was observed for 
Hispanic/Latinos and Asian or Pacific Islanders.  Since food items were added to the WHI 
FFQ to incorporate regional and ethnic foods in the United States.33, 42  The observed patterns 
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could be attributable to actual differences in consumption or the lack of ethnic foods 
containing betaine and choline.   
 Since women were enrolled throughout the calendar year across the United States and 
the measured time frame of this FFQ was “in the last 3 months”, it was possible to assess 
temporal variation in the estimated intakes of choline and betaine, allowing for possible 
variation in the availability of food items by region. A small variation of betaine and choline 
by geographic location was observed.   Median betaine intake was lower in the West region 
than those in the Northeast, South, and Midwest.  Median choline intake was higher in the 
Midwest compared to the Northeast, South, and West.  While previous studies have not 
examined choline and betaine estimates by geographic region, others have reported on the 
presence of macronutrient geographic variation.43 
 Similar to the analysis of geographic variation, we were able to investigate possible 
seasonal variation in intakes of choline and betaine, not addressed by previous studies, 
possibly because the other four studies utilized FFQs which inquired about diet over the last 
year in contrast to the WHI FFQ time frame of “in the last 3 months”.  Each region’s and 
race/ethnicity’s contribution to the total FFQs completed each month remained consistent.  
Both dietary choline and betaine intake appeared to vary by month within regions.  These 
variations were of small magnitude.  The food items which contributed the most towards 
choline and betaine intakes were mostly similar in each geographic region and across the 
race/ethnicity groups represented in this population.  We have shown that some of the 
differences by region and race/ethnicity in the total choline and betaine (mg/day) consumed 
could be accounted for by the differences in the amount of each item consumed (mg/day).  
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 The profiles of total choline and betaine intake were similar in the OS and DM arms 
of the study, as these groups had very similar estimated betaine and choline medians and IQR 
intakes.  We thus combined these groups in contextualizing the WHI estimates with the 
extant literature.  Bidulescu et al. 200718 used FFQs collected in the ARIC study from 1987-
1989, which is a large bi-ethnic prospective cohort (n=14,430) with participants of both 
genders who did not have a history of coronary heart disease.  Study participants, aged 45 to 
64 at enrollment, were recruited from Forsyth County, North Carolina; Jackson, Mississippi; 
suburbs of Minneapolis, Minnesota; Washington County, Maryland44.  Dalmeijer, et al 
200717 examined FFQs collected from 1993-1997 in the PROSPECT-EPIC study. This 
studied included 16,165 Dutch postmenopausal women, between the ages of 49 and 70 years, 
of the Dutch PROSPECT–EPIC cohort.  Cho et al. 200729 used the NHS FFQ data from 1984 
which consisted of 39,246 women, residents of the 11 of the larger US states, free from 
cancer or polyps.   Cho et al. 200641 used FFQs completed between 1991-1994 from the 
Framingham Offspring Study population, which consisted of individuals from Massachusetts 
between the ages of 33 and 87 years (920 men and 1040 women), who were free of 
diagnosed cardiovascular disease.   
 In addition to the population differences, each of these studies utilized a different 
version of the FFQ: a 66-item version of the Willett semi-quantitative food frequency 
questionnaire (ARIC); 178-item semi-quantitative FFQ for Dutch cohorts (PROSPECT-
EPIC); 131-item semi-quantitative FFQ (NHS); 131-item semi-quantitative FFQ 
(Framingham Offspring).  ARIC, NHS, and Framingham calculated choline and betaine 
using the USDA database contents of common US foods (Howe et al., 200414).  Similarly, 
PROSPECT-EPIC used the USDA Special Interest database.14   For items in the 
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questionnaire that did not have a direct correspondence to a food in the USDA database, they 
estimated the choline and betaine contents of nutritionally comparable foods that were 
available with the recipes of the NEVO table (Dutch food composition table) (NEVO, 
200145) and the recipes of a standard Dutch recipe book was used to decide on the individual 
components and their contribution to the mixed dish (Henderson et al., 199446). 
 
The observed differences of betaine and choline intake between studies are consistent with 
dissimilarities of the FFQ instruments used, conversion factors, population characteristics 
and geographic regions.  The lowest mean estimated choline intake (ARIC and WHI) were 
observed in the studies with the smallest number of FFQ items. Similarly, the substantially 
lower intake of betaine in the ARIC populations may plausibly be ascribed to the small 
number of items (66) on the FFQ employed.   
 Similar to the previous four large cohort studies, a limitation of this study is that the 
choline and betaine intake were estimated using a semi-quantitative dietary assessment tool, 
a FFQ, to asses dietary intake which tends to underestimate the absolute dietary intake for a 
particular nutrient.47  Further, population location statistics cannot be directly compared 
between studies which utilize different FFQs.  All four previous studies, as well as ours, 
report population dietary choline values substantially lower than the AI.  Fischer et al 200516 
demonstrated that differences between actual choline intake and those estimated from food 
records exist, where reported choline is considerably lower.  However, the proportion of 
choline which comprises the diet is similar for actual and reported diet.  These differences 
were attributed to underreporting of energy intake for food records.16   
 In conclusion, we estimated the dietary intake of choline and betaine in the OS and 
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DM components of the WHI using a semi-quantitative self-administered 122 item WHI FFQ 
completed at study baseline/ enrollment33 between 1993 and 1998.  In this first study of 
apparently healthy postmenopausal women (aged 50 to 79 years) from diverse racial/ ethnic 
and geographic (40 clinical centers throughout the United States) backgrounds, the dietary 
intake of choline and betaine is similar to that reported by previous more homogeneous 
studies in different locales..  Due to the WHI’s large sample size and emphasis on inclusion 
of racial/ethnic groups,30 we were able to characterize betaine and choline intake in self-
identified racial/ethnic sub-groups.  Modest variability in the dietary intake of betaine and 
choline were observed by self-identified race/ ethnicity, and by geographic region in the U.S. 
Although seasonal variability in the intake of choline and betaine can be detected, the 
magnitude of these variations is small.  The estimated population dietary choline values are 
lower than the 1998 AI established by the Food and Nutrition Board of the Institute of 
Medicine of the National Academy of Sciences.
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Table IV.1.1  Distribution of baseline Food Frequency Questionnaire and baseline 
characteristics of the Women’s Health Initiative (WHI) population (N = 138,612). 
Characteristic   WHI Group 
 
 
OS 
N=90,009  
DM 
N=48,603  
All 
N=138,612 
Age, y  63.6 ±7.4  62.3 ±6.9  63.1 ±7.2 
       
Race/ethnicity*, n (%)       
   White  75,859 (84.5)  39,573 (81.6)  115,432 (83.5) 
   Black  6,772 (7.5)  5,238 (10.8)  12,010 (8.7) 
   Hispanic/ Latino  3,248 (3.6)  1,831 (3.8)  5,079 (3.7) 
   Asian or Pacific Islander  2,501 (2.8)  1,102 (2.3)  3,603 (2.6) 
   American Indian or Alaskan 
Native 
 382 (0.4)  202 (0.4)  584 (0.4) 
   Other  997 (1.1)  559 (1.2)  1,556(1.1) 
       
Smoking, n (%)‡       
    Never  45,021 (50.7)  24,833 (51.7)  69,854 (51.1) 
    Past  38,253 (43.1)  19,997 (41.6)  58,250 (42.6) 
    Current  5,463 (6.2)  3,236 (6.7)  8,699 (6.4) 
       
Body mass index , kg/m2§       
    <25  36,450 (41.0)  12,597 (26.0)  49,047 (35.7) 
    25-<30  30,242 (34.0)  17,321 (35.8)  47,563 (34.6) 
    ≥30  22,269 (25.0)  18,472 (38.2)  40,741 (29.7) 
       
Dietary methionine, g/day  1.5±0.7  1.7±0.7  1.6±0.7 
       
Dietary fiber, g/day  16.5±7.0  15.4±6.4  16.1±6.8 
       
Dietary folate       
Total dietary folate   
equivalent from food 
frequency questionnaire  
and dietary supplements,     
µg/day 
 
639.6 ±479.2  541.6 ±422.5  605.2 ±462.5 
Dietary natural folate (food 
folate), µg/day 
 237.4 ±89.5  226.7 ±84.8  233.7 ±88.0 
       
Dietary saturated fatty acid, 
g/day 
 18.0 ±10.8  25.5 ±12.3  20.7 ±11.9 
Dietary cholesterol, mg/day  200.5±123.8  260.1±136.0  221.4±131.3 
       
Alcohol intake, g/day  5.6±11.2  4.4±8.5  5.2±10.3 
           
Abbreviations: DM, Dietary Modification Trial; OS, Observational Study; WHI, Women’s Health Initiative;  * 
Race/ethnicity missing for 250 OS and 98 DM participants; † Smoking missing for 1,272 OS and 537 DM participants ‡ 
Body mass index missing for 1,048 OS and 213 DM participants. 
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Table IV.1.2  Food item sources of choline and betaine in the Women's Health Initiative, 
estimated from the Women’s Health Initiative Food Frequency Questionnaire for all 
Observational Study and Dietary Modification Trial collected at the time of enrollment into 
the study 
  
 Choline   Betaine 
Rank Food  
Mean 
(mg) %*  Rank Food  
Mean 
(mg) %* 
1 Eggs 31.6 10.3  1 Bread 54.0 27.5 
2 Any Milk† 31.3 10.4  2 Greens 46.3 25.1 
3 Steak 18.8 6.3  3 Cold Cereal 30.8 15.4 
4 Chicken 18.8 6.8  4 Spaghetti 14.1 8.3 
5 Fish 10.2 3.7  5 Biscuit 7.2 4.0 
6 Ground Meat 9.7 3.4  6 Saltine 4.5 2.5 
7 Broccoli 8.9 3.4  7 Fish 4.5 2.8 
8 Coffee 8.7 3.4  8 Cookies 4.3 2.6 
9 Bread 7.7 2.8  9 Doughnuts 3.8 2.2 
10 Yogurt 6.6 2.3  10 Mac n' Cheese 3.1 1.8 
                 
*Average contribution towards individual’s total choline or betaine intake 
†Any Milk = milk from either cereal, drink, and cream 
‡Spaghetti = spaghetti with tomato sauce and spaghetti with meat sauce 
§ Steak = beef, pork, and lamb as a main dish, such as steak, roast and ham 
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 Table IV.1.3  Food item sources of choline and betaine in the Women's Health Initiative, estimated from the Women’s Health 
Initiative Food Frequency Questionnaire (FFQ) for all Observational Study and Clinical Trial participants by region of the United 
States collected at the time of enrollment into the study  
 
 
 
 Northeast 
 
South  Midwest  West 
Rank Food  
Mean 
(mg) %* 
 
Food  
Mean 
(mg) %*   Food  
Mean 
(mg) %*   Food  
Mean 
(mg) %* 
CHOLINE 
1 Any Milk 32.3 10.9  Eggs 30.9 10.0  Any Milk 36.8 11.8  Eggs 33.2 11.0 
2 Eggs 30.8 10.0  Any Milk 28.2 9.6  Eggs 31.0 9.7  Any Milk 29.3 9.9 
3 Chicken 19.7 7.2  Chicken 19.9 7.2  Steak 20.8 6.8  Steak 17.8 6.1 
4 Steak 18.3 6.2  Steak 18.7 6.4  Chicken 18.2 6.4  Chicken 17.5 6.4 
5 Fish 11.7 4.3  Fish 9.8 3.6  Ground Meat 11.7 3.9  Fish 9.9 3.6 
6 Broccoli 10.0 3.7  Ground Meat 9.6 3.4  Fish 9.4 3.3  Ground Meat 9.1 3.2 
7 Coffee 9.3 3.6  Broccoli 8.4 3.2  Coffee 9.0 3.3  Broccoli 9.0 3.5 
8 Ground Meat 8.9 3.1  Coffee 8.3 3.2  Bread 8.6 3.0  Coffee 8.4 3.3 
9 Bread 8.4 3.1  Bread 7.0 2.6  Broccoli 8.2 3.0  Bread 7.2 2.7 
10 Yogurt 7.5 2.7  Beans 7.0 2.6  Lunch Meat 6.6 2.2  Yogurt 6.5 2.4 
                               
BETAINE 
1 Bread 58.6 29.3  
Cooked 
Greens 63.2 32.9  Bread 59.7 30.0  Bread 50.4 27.7 
2 
Cooked 
Greens 47.9 24.2  Bread 49.0 24.4  Cold Cereal 32.9 16.3  
Cooked 
Greens 41.1 23.2 
3 
Cold 
Cereal 30.5 14.7  Cold Cereal 32.2 15.5  
Cooked 
Greens 31.3 16.8  Cold Cereal 28.1 15.2 
4 Spaghetti 18.5 10.4  Spaghetti 12.1 7.0  Spaghetti 13.1 7.6  Spaghetti 13.1 8.3 
5 Biscuit 7.1 3.8  Biscuit 8.3 4.5  Biscuit 6.9 3.8  Biscuit 6.4 3.9 
6 Cookies 4.9 2.8  Saltine 5.4 2.9  Fish 4.8 2.9  Cookies 4.0 2.7 
7 Doughnut 4.3 2.4  Fish 5.2 3.1  Cookies 4.7 2.8  Fish 4.0 2.6 
8 Saltine 4.3 2.2  Cookies 3.9 2.3  Saltine 4.6 2.5  Saltine 3.9 2.3 
9 Fish 4.2 2.5  Doughnut 3.7 2.2  Doughnut 4.2 2.5  Rice  3.4 2.4 
10 
Milk 2.8 1.7  
Mac and 
Cheese 3.2 1.8  Cheese 3.4 2.0  Doughnut 3.1 2.0 
*Average contribution towards individual’s total choline or betaine intake 
†Any Milk = milk from either cereal, drink, and cream 
‡Spaghetti = spaghetti with tomato sauce and spaghetti with meat sauce 
§ Steak = beef, pork, and lamb as a main dish, such as steak, roast and ham 
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Table IV.1.4  Food item sources of choline and betaine in the Women's Health Initiative, estimated from the Women’s Health 
Initiative Food Frequency Questionnaire (FFQ) for all Observational Study and Clinical Trial participants by race/ethnicity of the 
United States collected at the time of enrollment into the study 
 White Black   Hispanic/ Latino Asian or Pacific Islander 
Rank Food  
Mean 
(mg) %* Food  
Mean 
(mg) %* Food  
Mean 
(mg) %* Food  
Mean 
(mg) %* 
CHOLINE 
1 All Milk 33.1 11.0 Eggs 33.6 11.2 Eggs 38.6 13.0 Eggs 28.6 10.2 
2 Eggs 31.0 10.0 Chicken 28.4 10.8 All Milk 27.4 9.6 All Milk 20.5 7.5 
3 Steak 19.1 6.4 All Milk 19.3 6.8 Chicken 19.6 7.2 Steak 17.5 6.3 
4 Chicken 17.8 6.4 Steak 16.4 5.7 Steak 19.6 6.7 Rice 16.0 6.9 
5 
Ground 
Meat 10.0 3.5 Fish 13.2 5.0 
Ground 
Meat 10.1 3.5 Chicken 15.9 5.9 
6 Fish 9.8 3.5 Broccoli 9.4 3.8 Fish 8.7 3.2 Fish 14.3 5.5 
7 Coffee 9.2 3.5 Liver 9.1 2.8 Broccoli 7.4 2.9 Broccoli 9.1 3.7 
8 Broccoli 8.9 3.4 Ground Meat 7.6 2.7 Coffee 6.6 2.7 Ground Meat 6.9 2.6 
9 Bread 8.1 2.9 Beans 6.6 2.6 
Lunch 
Meat 5.9 2.1 Coffee 6.5 2.8 
10 Yogurt 6.9 2.5 Bread 6.3 2.5 Yogurt 5.9 2.2 Tofu 5.8 2.4 
                          
BETAINE 
1 Bread 56.5 29.0 Cooked Greens 116.9 63.4 
Cooked 
Greens 43.9 29.8 
Cooked 
Greens 97.1 52.0 
2 
Cooked 
Greens 37.1 19.3 Bread 44.0 21.3 Bread 36.4 21.9 Bread 33.9 19.2 
3 
Cold 
Cereal 32.8 16.4 Cold Cereal 21.3 10.0 
Cold 
Cereal 20.3 12.5 Cold Cereal 16.1 8.6 
4 Spaghetti 14.5 8.5 Spaghetti 11.3 6.3 Spaghetti 12.3 9.0 Spaghetti 10.5 6.6 
5 Biscuit 7.2 4.0 Fish 9.5 5.6 Biscuit 6.7 4.5 Rice 10.2 7.4 
6 Saltine 4.7 2.6 Biscuit 7.8 4.0 Fish 4.7 3.7 Fish 8.0 5.0 
7 Cookies 4.6 2.8 Saltine 4.2 2.2 Doughnut 4.3 3.3 Biscuit 5.0 3.1 
8 Fish 3.9 2.4 Doughnut 3.9 2.2 Rice 3.5 3.1 Yam 3.1 1.9 
9 Doughnut 3.8 2.2 Mac and Cheese 3.6 2.1 Saltine 3.4 2.4 Doughnut 3.0 2.0 
10 
Mac and 
Cheese 3.1 1.8 Yam 3.4 2.0 Meat 3.1 2.7 
Indian Fry 
Bread 2.5 1.7 
             
*Average contribution towards individual’s total choline or betaine intake 
†Any Milk = milk from either cereal, drink, and cream 
‡Spaghetti = spaghetti with tomato sauce and spaghetti with meat sauce 
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Table IV.1.5  Mean daily intake of choline, betaine, and total energy estimated from semi-quantitative food frequency questionnaires 
(FFQ) in the Atherosclerosis Risk in Communities (ARIC) Study; the Dutch Contribution to the European Prospective Investigation in 
Cancer and Nutrition (PROSPECT-EPIC); The Nurses’ Health Study; Women’s Health Initiative (WHI). 
 
 
 
ARIC18 WHI 
PROSPECT
–EPIC 
cohort17 
The 
Nurses’ 
Health 
Study29 
Framingham 
Offspring48 
 66 food item FFQ 122 food item FFQ 
178 food item 
FFQ 
131 food item 
FFQ 131 food item FFQ 
           
 
White 
Women 
Black 
Women 
All 
Women All 
White 
Women 
Black 
Women All Women Women Men Women 
 (N=6,043) (N=2,626) (N=8,669) (N=15,428) (N=115,432) (N=12,010) (N=138,612) (N=16,165) (N=39,246) (N=920) (N=1,040) 
Dietary Choline 
(mg/day)            
 Median  273   263 271 284 268 242 264 NA NA NA NA 
IQR 141 149  152 136 157 140     
 Mean  288   287 294 304 284 271 282 300 331 312* 314* 
SD 115 151 111 136 111 136 115 51 80   
95% Confidence 
Interval (285, 291) (281, 293) (292, 297) (302, 306)    (299, 301) (330, 332)   
            
Dietary Betaine 
(mg/day)            
 Median 90 88 89 94 166 164 164 NA NA NA NA 
IQR 60 56  64 114 133 116     
 Mean 99 99 102 106 183 191 182 241 189 200* 216* 
SD 48 53 47 54 94 113 96 74 97   
 95% Confidence 
Interval (98, 100) (97, 101) (101, 103) (105, 107)    (240, 242) (188, 190) NA NA 
            
Total Energy Intake 
(kcal) NA NA NA 1,625 (609) 1,656 (621) 1,624 (772) 1,648 (645) 1,798 (436) NA NA NA 
 
*Energy-adjusted means 
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Figure IV.1.1 Cumulative frequency distribution of mean daily choline and betaine 
consumption within the last 3 months, derived from the Women’s Health Initiative FFQ for 
all Observational Study and Clinical Trial participants collected around time of enrollment by 
race/ethnicity. 
A 
 
 B 
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Figure IV.1.2 Cumulative frequency distribution of mean daily choline and betaine 
consumption within the last 3 months, derived from the Women’s Health Initiative FFQ for 
all Observational Study and Clinical Trial participants collected around time of enrollment by 
United States region in which the participant resides. 
 A 
 
B 
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Figure IV.1.3 Mean choline consumption within the last 3 months, derived from the 
Women’s Health Initiative FFQ for all Observational Study and Clinical Trial participants 
collected around time of enrollment.  Mean choline mg/day consumption with upper and 
lower standard deviation boundaries are presented by United States region in which the 
participant resides and month when the FFQ was completed. 
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Figure IV.1.4 Mean betaine mg/day consumption within the last 3 months, derived from the 
Women’s Health Initiative FFQ for all Observational Study and Clinical Trial participants 
collected around time of enrollment.  Mean betaine mg/day consumption with upper and 
lower standard deviation boundaries are presented by United States region in which the 
participant resides and month when the FFQ was completed.   
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IV.2 Variability of betaine, choline, folate, methionine, vitamin B6 and vitamin 
B12 intake estimated from the WHI Food Frequency Questionnaire, and 
comparison to Four-Day Food Record data.  The Women’s Health Initiative 
(WHI) 
 
Introduction  
Methylation of DNA is essential for the regulation of gene expression, which in turn 
regulates cell differentiation,27, 48-50 and previous studies have reported associations between 
DNA hypomethylation and colorectal24 breast,25 and lung cancer.26, 27 Dietary betaine and 
choline are micronutrients involved in the methylation of homocysteine to form methionine. 
Dietary deficiency of choline and betaine decreases S-adenosylmethionine (SAM) 
concentrations, which results in hypomethylation of DNA51 SAM is the primary methyl 
donor for numerous biochemical reactions throughout human tissue.52 On an alternate 
pathway, deficiencies in dietary folate and vitamin B12 (B12) can also lead to decreases in 
SAM concentrations. 53   Dietary betaine and choline intake may also be associated with 
coronary heart disease (CHD) through the homocysteine methylation pathway. Elevated 
plasma homocysteine levels have been associated with coronary and cerebral vascular 
disease, as well as risk of arterial thromboembolism, in observational studies,54-57 although 
associations have not been confirmed by clinical trials of homocysteine modification via 
supplementation with folic acid, vitamin B6 (B6) and B12 (e.g., VISP,15 NORVIT,16 
HOPE217).   
 
Data required to estimate choline and betaine intake from common foods in populations were 
insufficient until the recent development of the United States Department of Agriculture 
(USDA) Special Interest database for choline and betaine in foods. 13, 14 Since then, several 
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cohort studies have examined the relation between habitual dietary choline and betaine intake 
(estimated with different versions of Food Frequency Questionnaires [FFQs]), and incident 
CHD,18 cardiovascular disease risk factors,17 and distal colorectal adenoma.29  The impact of 
variability in intake estimation attributable to instrument and within-person variation was 
considered by only one study.37   Since this information is largely missing from the literature 
we ascertained: (1) the variability in the Women’s Health Initiative (WHI) FFQ with 
reference to a four-day food record (FDFR) and (2) intra-individual one-year variability in 
WHI FFQ measurements of estimated intakes of betaine, choline, folate, methionine, B6 and 
B12. We also assessed the WHI FFQ measurement error and studied the intra-individual 
variability when several related nutrients are considered simultaneously. 
 
Methods 
Study Population 
 The study population is drawn from the Observational Study and the Dietary 
Modification Trial (DM) components of the WHI, as a WHI FFQ was administered at 
baseline in both studies and DM trial participants also completed a FDFR at baseline. 
Recruitment of postmenopausal women aged 50 to 79 years who were interested in one or 
more components of the clinical trials was conducted at 40 clinical centers throughout the 
United States between October 1, 1993 and December 31, 1998. Potential participants were 
excluded if they did not plan to reside in the area near the respective clinical center for at 
least three years, had medical conditions predictive of survival less than three years, or had 
complicating conditions such as alcoholism, drug dependency, or dementia. All participants 
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provided informed consent using materials approved by institutional review boards at each 
center.  
 
Observational Study. Participants were enrolled in the Observational Study if they expressed 
an interest in either the DM or hormone therapy components of the clinical trial, but were 
ineligible or unwilling to participate in the clinical trial component to which they were 
assigned, or if they responded to a direct invitation from the WHI to be screened for 
enrollment into the Observational Study.  
 
Dietary Modification Trial (DM). Eligibility criteria for the dietary modification trial 
included willingness to be randomized to an intervention or comparison group and having a 
fat intake at baseline that accounted for 32% or more of total caloric intake as estimated 
based on the WHI FFQ.33  The most common reasons for exclusion included any prior 
colorectal cancer or breast cancer, other cancers in the previous 10 years, Type 1 diabetes, 
medical conditions with predicted survival of less than 3 years, or adherence concerns, 
including having meals frequently prepared away from home.  
 
Dietary Assessment 
WHI FFQ. Food and nutrient intake were assessed by a semi-quantitative, self-administered, 
122 item FFQ based on instruments previously used in the Women’s Health Trial Vanguard34 
and Full Scale Studies,35 the Working Well Trial,36 and the Women’s Health Trial Feasibility 
Study in Minority Populations.37 At enrollment, all participants completed an FFQ designed 
specifically for the WHI study whose measurement characteristics are reported elsewhere.33 
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Participants with reported total energy intakes values outside of > 5,000 kcal or < 600 kcal 
were considered implausible and thus excluded. 38 Additionally, we excluded observations 
with estimated intakes above the 99th percentile for betaine, choline, natural folate, dietary 
folate equivalents (DFE), B6, B12, and methionine analyses respectively, to minimize the 
possible effects of influential values. 
 
FDFR. At baseline, all women participating in the DM completed a FDFR. Participants 
received instructions on how to keep an accurate food record including: written instructions; 
a 15- minute videotape; 15–30 minutes of additional instruction from study-certified clinical 
staff.33  The FDFR was kept on four alternate days, including a Saturday or Sunday. 
Participants mailed completed records to the WHI Clinical Coordinating Center (CCC), 
where staff reviewed them and contacted participants if there were incomplete food 
descriptions or missing portion sizes.  
 
Conversion. As part of this ancillary study, the WHI CCC converted food item data into 
estimates of total daily intake of choline and betaine using the Nutrition Data System for 
Research (NDS-R) software version 2007,40 developed by the Nutrition Coordinating Center, 
University of Minnesota, Minneapolis, MN which utilizes USDA Standard Reference 1961. 
This database includes over 18,000 foods of which 8,000 are name brand products. The WHI 
CCC developed a custom software program that passes the scanned data from the FFQ 
through the nutrient database to yield estimates of each person’s daily intake of over 155 
nutrients, nutrient ratios, and other food components. Reported quantities are converted into 
gram weights and food identification codes are linked with corresponding nutrient values.  
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 Unlike the FFQs, not all FDFRs were analyzed in the trial cohort due to costs. 
Instead, FDFRs were processed by nutritionists into a newer version of the database62-65 for a 
DM case-only analysis for study participants who subsequently developed breast cancer, 
colorectal cancer, ovarian cancer, and coronary heart disease.  
 
Statistical Analyses 
Within person one-year variability.  Participants with an incident chronic disease (cancer, 
coronary heart disease, congestive heart failure, peripheral artery disease, stroke classified 
per the WHI outcomes protocol) within one year after enrollment were excluded, to avoid 
potential changes in diet associated with subclinical disease states. We estimated the within-
person repeatability of the WHI FFQ in DM Usual Diet arm participants who completed a 
WHI FFQ at both enrollment and at one-year follow-up. Linear mixed-effects models were 
used to estimate the various components of total variation in the dietary data. We partitioned 
the total variance (σT2) into between-pair (σBP2) and intra-individual (σe2) variance 
components by treating paired FFQ measurements as random effects in linear mixed-effects 
models. The proportion of the total variance attributable to between-person variability, or the 
reliability coefficient (R = σBP2 / σT2), was interpreted as the correlation between paired 
measurements. We obtained separate reliability coefficients for betaine, choline, methionine, 
total folate (DFE), natural folate, B12, and B6. We also calculated reliability coefficients in 
models when all of the micronutrients were considered simultaneously.  The coefficient of 
variation (CV) was used to express the standard deviation as a percentage of the mean, 
calculated as the square root of the within-pair variance component divided by the mean of 
the paired observations, multiplied by 100. The following benchmarks were used for 
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characterizing the reliability of the intake measurements: slight reliability, 0.00-0.20; fair 
reliability, 0.21-0.40; moderate reliability, 0.41-0.60; substantial reliability, 0.61-0.80; almost 
perfect reliability, 0.81-1.00. 66 Bland-Altman plots were used to characterize the degree of 
disagreement between the baseline and one-year subsequent FFQ measures and to identify 
outliers and trends.61 
 
Agreement between FFQ and FDFR. We also sought to determine the concordance between 
baseline estimates of dietary betaine, choline, methionine, natural folate, total folate, B12, and 
B6 from the WHI FFQ with those from the FDFR for DM study participants. For this we used 
Pearson product-moment correlations to quantify the degree of linear association between 
food and nutrient intake estimates measured by the FFQ with those measured by the FDFR. 
Linear regression models were fitted using FDFR and FFQ nutrient intakes estimates.67 The 
resulting regression lines were plotted against scatter plots of the actual data. 
 
Results 
Repeatability of WHI FFQ Dietary Intake. The Usual Diet arm of the DM included 29,294 
postmenopausal women. After excluding 2,602 women with missing baseline or one-year 
subsequent dietary information, 650 with implausible daily caloric intake values (< 600 
kcal/day or > 6000 kcal/day), and 341 with incident disease (i.e., cancer, coronary heart 
disease, congestive heart failure, peripheral artery disease, and stroke) within one year of 
enrollment, 25,701 (87.7%) observations remained with both baseline and one-year repeat 
WHI FFQ data for analysis (Figure IV.2.1). As shown in Table IV.2.1, the characteristics of 
the final sample of Usual Diet Arm (Repeat FFQ) were similar to the full set of 29,294 
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participants in the DM (83.4% vs. 81.6% European Americans, 47.6% vs. 48.4% current or 
former smokers, and 37.0% vs. 38.2% BMI ≥30 kg/m2.  
Table IV.2.2 presents the repeatability estimates for betaine, choline, methionine, 
natural folate, total folate, B12, and B6 WHI FFQ intake estimates. Variability based on the 
CV was lowest for natural folate (27.2%) followed by choline (28.1%), total folate (29.2%), 
B6 (29.3%), methionine (29.4%), and betaine (33.6%); whereas B12 (37.1%) showed the 
highest variability. Visual inspection of the Bland-Altman plots suggests increasing 
variability of differences with increasing mean values of each of the nutrients at baseline 
(Figure IV.2.2A-G). When the size of the relative differences is plotted against the mean of 
the pairs, they are fairly uniform until near the 97th percentile, and then they approach 0.  
 Individual mixed models were constructed for each micronutrient to assess intra-
individual variability between the two visits (Table IV.2.2).   Coefficients didn't vary 
substantially when multiple micronutrients were entered simultaneously (betaine) 0.50, 
(choline) 0.59, (total energy intake) 0.55, (total folate) 0.30, (B6) 0.60, (B12) 0.55, and 
(methionine) 0.56 (Table IV.2.3).  
 
Agreement between FFQ and FDRFR. A total of 4,629 food records for DM case-only 
(breast cancer, colorectal cancer, ovarian cancer, and coronary heart disease cases) 
participants were re-entered by nutritionists into the newer version of the database.62-65 Of 
these 4,629, both a food record and WHI FFQ were completed at baseline by 4,615 of these 
participants. Five participants reported implausible WHI FFQ daily caloric intake values at 
baseline and 135 participants did not have food records that covered four days, which 
resulted in 4,475 (96.7%) participants for analyses comparing the FDFR to the FFQ.   
  118 
 When compared to the DM trial source population, the case-only subset included a 
higher proportion of European Americans (85.6% vs. 81.6%), current or former smokers 
(50.7% vs. 48.4%), and obese (BMI ≥30 kg/m2; 40.7% vs. 38.2%) (Table IV.2.1). On 
average, the case-only subset was 1.5 years older than overall DM trial participants. The 
correlations between the FFQ average daily intakes and estimates from the FDFR were 
highest for natural folate (0.321), choline (0.304), and methionine (0.268) (Table IV.2.4). 
Correlations were lowest for betaine (0.220), total folate (0.121), B6 (0.081), and B12 (0.098) 
(Table IV.2.4), as evidenced by greater spread of individual observations about the 
regression lines for each nutrient (Figure IV.2.3).  For all micronutrients but Vitamin B6 and 
B12, whose correlation is consistently poor for all range of values, the spread about the 
regression lines increase with increasing levels of estimated micronutrient intake.  
 
Discussion 
         This is the first study among women ages 50-79 years examining micronutrient methyl 
donor intra-individual one-year variability of the 122-item WHI FFQ and consistency of 
measurement between the WHI FFQ and FDFR. When using the benchmarks of: slight 
reliability, 0.00-0.20; fair reliability, 0.21-0.40; moderate reliability, 0.41-0.60; substantial 
reliability, 0.61-0.80; almost perfect reliability, 0.81-1.0035, the baseline and one-year FFQ 
estimates for the micronutrients, except that for DFE, moderately corresponded over time, 
but the FDFR and FFQ estimates were only slightly-to-fairly correlated.  
Quantifying variability in WHI FFQ estimates of dietary methyl donor is important 
when examining their associations with health outcomes.  Dietary deficiencies of betaine and 
choline9 and, on an alternate pathway, folate and B12,53 can lead to decreases in SAM 
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concentrations which result in hypomethylation of DNA. Hypomethylation has been linked 
to transformation, oncogene expression, and tumor progression68-71 thereby providing a basis 
for primary tumor growth and metastasis.72 Previous studies have reported associations 
between DNA hypomethylation and colorectal24, breast,25 and lung cancer.26, 27 DNA 
hypomethylation also provides a basis for atherogenesis.73-75 
Dietary betaine and choline intake may also be associated with CHD through the 
homocysteine methylation pathway. Elevated plasma homocysteine levels are reportedly 
correlates of coronary and cerebral vascular disease, as well as arterial thromboembolism.54-
57  Homocysteine, a breakdown product of methionine, is further degraded to cysteine 
through B6 dependent reactions.76 Alternatively, homocysteine is methylated to form 
methionine in a reaction catalyzed by betaine homocysteine methyltransferase, where betaine 
is the methyl donor for the reaction.77  Therefore, it is plausible that habitual dietary methyl 
donor intake levels may be associated with incident CHD.  
Population estimates of dietary betaine and choline intake have been reported in four 
large cohort studies: the Atherosclerosis Risk in Communities Study (ARIC) 18 the Nurses’ 
Health Study;29 the Framingham Offspring study;41 and cohort of the Dutch contribution to 
the European Prospective Investigation into Cancer and Nutrition (PROSPECT-EPIC).17 
Possible sources of variability in intake estimation attributable to within-person variation 
were discussed only in the ARIC study. Specifically, the authors evaluated the within-person 
variability of Willett semi-quantitative FFQ in a random sample of 1,004 participants whose 
dietary intake was measured at ARIC baseline and three years later.78 
Findings from ARIC were consistent with previous studies where the reliability 
(reproducibility) of micronutrient intake, as assessed with an FFQ, were lower than the 
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reliability of estimated intakes of macronutrients.33, 78-80 As expected, the WHI FFQ 
demonstrated moderate one-year reliability (reliability coefficients 0.30-0.60) for 
micronutrient intake estimates of the methyl donors: folate, B6, B12, methionine, choline, and 
betaine. When several related nutrients were considered simultaneously, along with total 
energy, the variability for each WHI FFQ estimated nutrient was similar to that obtained 
from individually calculated reliability coefficients estimated between the two visits with no 
one micronutrient differing by more than 0.01. Bidulescu et al. (2009) evaluated within-
person variation of the 66-item version of the Willett semi-quantitative FFQ in ARIC over a 
longer period of time (three years). The Bidulescu et al. estimates of reliability, which were 
based on a random sample of 1,004 participants whose dietary intake was measured at ARIC 
baseline and three years later, were similar to the one-year reliabilities observed in the 
present study with jointly-estimated reliability coefficiencts of total choline (choline + 
betaine) 0.50, folate 0.53, and methionine 0.48.78   Although our analysis also indicated 
moderate reliability for the one-year WHI FFQ, there was markedly high variability with 
CVs ranging from 27.2- 37.1 across micronutrients meaning the reliability of each of these 
micronutrients differs from each other. The Bland-Altman plots (Figure IV.2.2A-G) indicate 
that the difference of the paired methyl donor measurements is positively associated with the 
mean of the FFQ estimates. Similar metrics were not presented within Bidulescu et al. 
analysis.  
 The agreement between FDFR and FFQs estimates was modest (Pearson correlation 
coefficients 0.08- 0.32). A weak relation between estimates is to some degree expected given 
that the FDFR captures complete details of diet on four specific days while the FFQ 
estimates usual dietary intake over a time frame of “the last 3 months”. Objective biomarkers 
  121 
have been successfully used in WHI to calibrate self-reports but, biomarkers are not available 
for the nutrients addressed in this report. Therefore, FDFRs were used as a gold standard for 
calibration of the estimates from FFQs. 
The food records used to compare FDFRs to FFQs came from DM participants who 
over the course of follow-up developed breast cancer, colorectal cancer, ovarian cancer, or 
coronary heart disease cases. All FDFRs and FFQs from this case-only subset were 
completed prior to case diagnosis; while it is possible that subclinical disease could have 
affected the participants’ diets in advance of manifest morbidity, it is less likely that it would 
have influenced the way in which an individual completes both the FFQ and FDFR. 
Therefore, it is unlikely that case status affected the observed relation between the FFQ and 
FDFR.  One limitation of the FFQ repeatability analysis is the one-year long interval between 
FFQ assessments, which may have resulted in changes in dietary intake over time. This may 
have contributed to the modest level of repeatability we observed.  Intraindividual variation 
could not be estimated for the FDFR as only baseline assessments were available.   
In conclusion, the baseline and one-year FFQ estimates for the micronutrients showed 
moderate agreement, with the exception of total folate (DFE). In contrast, micronutrients 
estimated from FDFR and FFQs were only slightly-to-fairly correlated. Due to the WHI’s 
large sample size, we were able to estimate the joint intra-individual variability for all 
interrelated micronutrients including betaine, choline, total energy intake, total folate, B6, 
B12, and methionine. Exposure measurement error can bias measures of association and result 
in underestimation of their variance affect the power of statistical tests for association. 81, 82 83 
Given the observed moderate reliability of the FFQ for most micronutrients when 
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administered one year apart, variability should be considered when estimating intake levels 
of these micronutrients, as well as their associations with health outcomes. 
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Figure IV.2.1 Participant Flow in the Dietary Modification Usual Diet Arm Component of 
the Women’s Health Initiative 
 
 
 
 
 
 
 
 
 
 
 
 
 29,294 Were Assigned to Receive Usual Diet 
26,692 Have Baseline and One-year Dietary Information 
     78 Missing Baseline Dietary Information  
2,553 Missing One-year Dietary Information 
2,602 Missing Dietary Information for Either 
 
     34 Implausible Baseline Total Energy 
   625 Implausible One-year Total Energy 
   650 Implausible Total Energy for Either 
  
 
26,042 Have Repeat FFQ Analysis with Plausible Total Energy 
25,701 Included in the Repeat FFQ Analysis 
341 With One or More Incident Disease Cases Between 
FFQs: 
• 32 Stroke 
• 192 Cancer 
• 58 Coronary heart disease 
• 19 Congestive heart failure 
• 63 Coronary revascularization 
• 6 Periphjeral artery disease 
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Table IV.2.1  Distribution of baseline Food Frequency Questionnaire (FFQ) and baseline 
characteristics of the Women’s Health Initiative Dietary Modification Trial (DM) population 
overall; by Usual Diet participants who completed a FFQ at baseline and one-year follow-up; 
and case-only analyses (breast cancer, colorectal cancer, ovarian cancer and coronary heart 
disease cases) DM participants. 
 
Baseline Characteristics  DM 
N=29,294 
 Repeat 
FFQ* 
N=25,701        
 
FFQ and 
FDFR† 
N=4,475 
Age, y  62.3± 6.9  62.4± 6.8  63.9± 6.8 
       
Race/ethnicity, n (%)‡ 
 
     
   White 
 
39,762 (81.6)  21,386 (83.4)  3,821 (85.6) 
   Black 
 
5,262 (10.8)  2,427 (9.5)  390 (8.7) 
   Hispanic/ Latino 
 
1,845 (3.8)  857 (3.3)  112 (2.5) 
   Asian or Pacific Islander 
 
1,105 (2.3)  601 (2.3)  82 (1.8) 
   American Indian or Alaskan Native 
 
202 (0.4)  93 (0.4)  13 (0.3) 
   Other  560 (1.2)  289 (1.1)  45 (1.0) 
       
Smoking, n (%)§ 
 
     
    Never 
 
24,947 (51.7)  13,342 (52.4)  2,178 (49.3) 
    Past 
 
20,101 (41.6)  10,477 (41.2)  1,908 (43.2) 
    Current 
 
3,250 (6.8)  1,631 (6.4)  331 (7.5) 
       
Body mass index , kg/m2|| 
 
     
    <25 
 
12,659 (26.0)  6,869 (26.9)  1,087 (24.4) 
    25-<30 
 
17,396 (35.8)  9,244 (36.1)  1,558 (34.9) 
    ≥30 
 
18,567 (38.2)  9,472 (37.0)  1,814 (40.7) 
       
           
Abbreviations: WHI, Women’s Health Initiative; DM, Dietary Modification Trial; FFQ, Food Frequency Questionnaire; FDFR, Four-day 
Food Record 
* DM Trial Usual Diet arm participants who completed a FFQ at baseline and one-year follow-up 
† DM trial participants who completed a FFQ and four-day food record at baseline and were incident cases (breast cancer, colorectal cancer, 
ovarian cancer and CHD cases) during follow up/ 
‡ Ethnicity missing for 99 Usual Diet Arm, 48 Repeat FFQ, 12 FFQ and FDFR  
§ Smoking missing for 537 Usual Diet Arm, 251 Repeat FFQ, 58 FFQ and FDFR  
|| Body mass index missing for 213 Usual Diet Arm, 116 Repeat FFQ, 16 FFQ and FDFR 
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Table IV.2.2  Distribution of folate, B6, B12, methionine, choline and betaine intakes 
estimated from the Women’s Health Initiative Usual Diet participants who completed a Food 
Frequency Questionnaire at baseline and one-year follow-up (n=25,701). 
 
     IQR     
Variable N Mean SD Median Q1 Q3 Min Max R* CV 
Betaine (mg/day)           
    Baseline 25,222 178.3 83.0 164.8 116.6 226.2 8.4 476.8 0.49 33.6 
    Follow-up 25,222 166.2 79.8 152.5 107.8 211.1 12.3 469.2 
           
Choline (mg/day)           
    Baseline 25,238 294.1 107.0 280.4 215.8 357.7 63.6 669.8 0.58 28.1 
    Follow-up 25,238 274.3 99.6 261.4 201.5 333.4 63.9 626.9 
           
DFE (µg/day)           
    Baseline 25,223 253.9 116.9 229.9 176.0 299.4 31.7 801.8 0.31 29.2 
    Follow-up 25,223 338.7 170.8 299.8 208.6 438.0 45.8 986.5 
           
Natural Folate 
(µg/day)           
    Baseline 25,238 224.4 76.2 217.3 169.0 272.3 30.0 472.0 0.61 27.2 
    Follow-up 25,238 219.8 76.1 212.1 164.3 267.1 33.1 465.1 
           
B6 (mg/ day)           
    Baseline 25,239 1.6 0.6 1.5 1.1 1.9 0.3 3.6 0.59 29.3 
    Follow-up 25,239 1.5 0.6 1.5 1.1 1.9 0.3 3.6 
           
B12 (mcg/ day)           
    Baseline 25,233 6.2 3.0 5.7 4.0 7.8 0.4 18.6 0.54 37.1 
    Follow-up 25,233 5.8 2.9 5.3 3.7 7.3 0.1 17.9 
           
Methionine (g/day)           
     Baseline 25,232 1.7 0.6 1.6 1.2 2.0 0.2 3.9 
0.55 29.4 
     Follow-up 25,232 1.5 0.6 1.4 1.1 1.9 0.2 3.6 
     *Intraclass correlation coefficient of the repeated Food Frequency Questionnaire measurements 
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Table IV.2.3  Components of reliability and measurement error expressed as ratios of 
between-person variance or covariance to total (co)variance for related dietary nutrients 
estimated from the Women’s Health Initiative Usual Diet participants who completed a Food 
Frequency Questionnaire at baseline and one-year follow-up (N= 25,701) 
  Betaine Choline 
Total 
Energy 
Intake Folate Methionine 
Vitamin 
B12 
Vitamin 
B6 
Betaine 3,524 2,180 16,533 1,830 13 51 13 
0.50       
         
Choline  4,949 26,037 2,067 28 101 20 
0.59 0.59      
         
Total 
Energy 
Intake 
  191,878 10,043 161 544 119 
0.55 0.58 0.55     
         
Folate    16,779 10 52 16 
0.68 0.74 0.78 0.30    
         
Methionine     192 640 121 
0.58 0.58 0.56 0.77 0.56   
         
Vitamin B12 
     422 52 
0.60 0.60 0.58 0.71 0.58 0.55  
         
Vitamin B6 
      14 
0.61 0.61 0.59 0.68 0.60 0.60 0.60 
         
                  
Note 1: The ratios of between person-variance to total variance are the reliability coefficients (presented in bold 
italic) 
Note 2: The value presented on the diagonal of the table are the values for the error variance (italic) and off-
diagonal   numbers are the covariance error terms 
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Table IV.2.4  Baseline distribution of folate, B6, B12, methionine, choline and betaine intakes 
estimated from the Women’s Health Initiative Food Frequency Questionnaire and Four-day 
Food Record in case-only analyses (breast cancer, colorectal cancer, ovarian cancer and 
coronary heart disease cases) Dietary Modification Trial participants (n=4,475). 
 
Variables N Mean  Std Dev Median 
IQR 
mg/day 
Min Max R* Q1 Q3 
Betaine (mg/ day)          
   WHI FFQ 4,388 177.2 84.0 163.1 116.1 225.0 23.3 488.1 
0.220     4-day FR 4,388 187.8 92.4 168.5 125.2 225.3 10.5 624.5 
          
Choline (mg/ day)          
   WHI FFQ 4,393 290.3 108.5 276.3 209.7 352.9 64.3 684.8 
0.304     4-day FR 4,393 270.1 71.9 264.7 216.9 315.8 80.2 508.1 
          
DFE (µg/ day)          
   WHI FFQ 4,387 249.0 116.4 227.0 171.2 294.8 54.4 809.9 
0.121     4-day FR 4,387 786.2 440.0 623.2 435.0 1142.9 114.7 2,405.9 
          
Natural  
Folate (µg/ day)          
   WHI FFQ 4,389 222.0 77.5 214.2 164.6 271.6 46.5 467.1 
0.321     4-day FR 4,389 218.8 71.8 209.4 167.5 260.0 43.9 469.2 
          
B6 (mg/ day)          
   WHI FFQ 4,388 1.6 0.6 1.5 1.1 1.9 0.3 3.6 
0.081     4-day FR 4,388 2.7 3.0 1.9 1.4 3.3 0.3 51.9 
          
B12 (mcg/ day)          
   WHI FFQ 4,387 6.2 3.2 5.6 3.9 7.9 0.4 20.8 
0.098     4-day FR 4,387 8.5 9.0 5.7 3.4 10.1 0.2 109.8 
          
Methionine (g/ day)          
   WHI FFQ 4,392 1.6 0.7 1.6 1.1 2.0 0.2 3.9 
0.268     4-day FR 4,392 1.5 0.4 1.4 1.2 1.7 0.5 2.7 
          
* Pearson correlation coefficients 
 
 
 
  
 
          
128 
Figure IV.2.2 Bland-Altman plot showing bias against the mean of betaine, choline, B6, B12, natural folate, dietary folate equivalents, and 
methionine measurements obtained baseline and one year with 95% levels of agreement (broken lines) estimated from the Women’s Health 
Initiative Usual Diet participants who completed a Food Frequency Questionnaire at baseline and one-year follow-up. 
      A   Difference of Betaine Measurements (n=25,222) 
 
 
 
 
 
 
 
 
 
 
 
 
 
        B  Difference of Choline Measurements (n=25,238) 
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       C  Difference of Vitamin B6 Measurements (n=25,239) 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
  D  Difference of Vitamin B12 Measurements (n=25,233) 
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       E  Difference of Natural Folate Measurements (n=25,238). 
 
 
 
    
     
 
 
 
 
 
 
 
 
 
 F  Difference of Dietary Folate Equivalents Measurements (n=25,223) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean of Food Frequency Questionnaire Dietary Folate Equivalents Estimates 
D
iff
er
en
ce
 o
f N
at
ur
al
 F
ol
at
e 
 
 
 
 
 
 
 
D
iff
er
en
ce
 o
f D
ie
ta
ry
 F
ol
at
e 
Eq
ui
va
le
nt
s 
M
ea
su
re
m
en
ts
 
Mean of Food Frequency Questionnaire Dietary Natural Folate Estimates 
  
 
          
131 
 
 
 G  Difference of Methionine Measurements (n=25,232). 
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Figure IV.2.3 Scatter plots with regression lines and 95% confidence limits for nutrient intakes estimated from baseline food 
frequency questionnaires (FFQ) and four day food record (FDFR) estimated from the Women’s Health Initiative in case-only analyses 
(breast cancer, colorectal cancer, ovarian cancer and coronary heart disease cases) Dietary Modification Trial participants (n=4,475). 
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C) Dietary Folate Equivalents                                                                 D) Natural Folate 
 
 
 
 
 
 
 
 
 
 
 
 
E) Vitamin B-6                                                                                          F) Vitamin B-12 
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E) Vitamin B-12                                                                                  F) Vitamin B-6 
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G) Methionine 
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IV.3 Choline and Betaine Habitual Intake and Incident Coronary Heart Disease 
in the Women’s Health Initiative 
 
 
INTRODUCTION 
  Increased whole blood levels of total choline have previously been found to be 
associated with cardiovascular disease.84, 85 Two large cohort studies examined the relation of 
choline and betaine with incident cardiovascular disease and its risk factors. Dalmeijer et al. 
2007 found an inverse association of betaine intake with HDL-cholesterol, while 
homocysteine levels were inversely associated with choline, but not to betaine intake.17  
Bidulescu et al. 2007 reported that, compared with the lowest quartile of intake, the risk of 
incident CHD was slightly higher in the highest quartile of choline and choline plus betaine, 
yet confidence intervals included the null. 18  The impact of variability in intake estimation 
attributable to instrument and within-person variation on such associations was only 
considered by the latter study.18  It is not clear if the null findings from this study are related 
to the large measurement error of intake estimates for micronutrients such choline and 
betaine. 18     
Since this measurement error information is largely missing from the literature we 
ascertained: (1) intra-individual one-year variability in WHI FFQ measurements of betaine, 
choline, folate, methionine, B6 and B12 and (2) based on the former we estimated the 
association corrected for reliability between habitual intake of choline and betaine and 
incident coronary heart disease in the WHI. 
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METHODS 
Study Population 
 The primary analysis population is drawn from the Observational Study (OS), 
however within-person repeatability for WHI FFQ methyl donor estimates was obtained 
from the Dietary Modification (DM) Usual Diet arm. Recruitment into the WHI of 
postmenopausal women aged 50 to 79 years who were interested in one or more components 
of the clinical trials was conducted at 40 clinical centers throughout the United States 
between October 1, 1993 and December 31, 1998. Potential participants were excluded if 
they did not plan to reside in the area for at least three years, had medical conditions 
predictive of survival less than three years, or had complicating conditions such as 
alcoholism, drug dependency, or dementia. All participants provided informed consent using 
materials approved by institutional review boards at each center.  
 
Observational Study (OS). Participants were enrolled in the OS if they were ineligible or 
unwilling to participate in the clinical trial component to which they were assigned, or if they 
responded to a direct invitation from the WHI to be screened for enrollment into the OS.  
 
Dietary Modification Trial (DM). Eligibility criteria for the dietary modification trial 
included willingness to be randomized to an intervention or comparison group and having a 
fat intake at baseline that accounted for 32% or more of total caloric intake as estimated 
based on the WHI FFQ.9 The most common exclusions included any prior colorectal cancer 
or breast cancer, other cancers in the previous 10 years, Type 1 diabetes, medical conditions 
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with predicted survival of less than 3 years, or adherence concerns, including having meals 
frequently prepared away from home.  
 
Dietary Assessment 
Food and nutrient intake were assessed by a semi-quantitative, self-administered, 122 
item FFQ based on instruments previously used in the Women’s Health Trial Vanguard34 and 
Full Scale Studies,35 the Working Well Trial,36 and the Women’s Health Trial Feasibility 
Study in Minority Populations.37 At enrollment, all participants completed an FFQ designed 
specifically for the study whose measurement characteristics are reported elsewhere.33 
Participants with reported total energy intakes values outside of > 6,000 kcal or < 600 kcal 
were excluded considered implausible.38 
 As part of this ancillary study, the WHI CCC converted food item data into estimates 
of total daily intake of choline and betaine using the Nutrition Data System for Research 
(NDS-R) software version 2007,40 which utilizes USDA Standard Reference 1961 developed 
by the Nutrition Coordinating Center, University of Minnesota, Minneapolis, MN. This 
database includes over 18,000 foods of which 8,000 are name brand products. The WHI CCC 
developed a custom software program that passes the scanned data from the FFQ through the 
nutrient database to yield estimates of each person’s daily intake of over 155 nutrients, 
nutrient ratios, and other food components. Reported quantities are converted into gram 
weights and food identification codes are linked with corresponding nutrient values.  
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Outcome Ascertainment and Classification 
Methods for ascertaining and classifying outcomes in the WHI have been published.86 
Composite CHD was defined to include myocardial infarction (MI), CHD death, and 
coronary revascularization. MI includes both definite and probable MI events. 86 CHD death 
was defined as death consistent with CHD as the underlying cause plus one or more of the 
following: preterminal hospitalization with MI within 28 days of death; previous angina or 
MI and no potentially lethal non-coronary disease process; death resulting from a procedure 
related to coronary artery disease; or death certificate consistent with CHD as the underlying 
cause.86 Coronary revascularization included any coronary artery bypass graft surgery or, 
percutaneous transluminal coronary angioplasty, coronary stent, or coronary atherectomy.  
Both in-patient and out-patient percutaneous coronary interventions were included as events. 
 
Statistical Analyses 
The metabolic relationship between choline and betaine is recognized and the distributions of 
choline alone and choline + betaine by demographic and baseline characteristics are 
described. 19 We examined the association between choline alone and choline + betaine with 
the risk of CHD through 12 years of follow-up.  
 
When analyzing dietary macro- and micro- nutrients the total energy intake of the 
participant was considered.  Inter-individual differences in total energy intake can be 
attributed to physical activity, body size, and metabolic activity,87, 88 each of which may be 
related to incident coronary heart disease.  We thus adjusted for energy intake, in order to 
determine whether the macro- and micro-nutrients affect the risk of disease via a pathway 
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other than energy production.89 The effect of total energy was examined using a nutrient 
density approach, where dietary B vitamin intake was examined using nutrient densities 
(units of nutrient/kilocalorie).90, 91 
Multivariable-adjusted associations, with their 95% CIs, between nutrient density 
choline and the incidences through 12 years of CHD were estimated by Cox proportional 
hazard regression models 92 using SAS Version 9.2 (SAS Institute Inc., Cary, NC).  Survival 
analysis models were constructed by race (White and Black).   The time scale for all analysis 
was person-time in study accrued from the enrollment date.  Follow-up time ended at death, 
the occurrence of CHD endpoint date of censoring or at loss to follow-up.  Individuals who 
were event-free throughout the follow-up period were censored.  The proportional hazards 
assumption was verified using plots of the log (-log) survival curves and using the Cox test 
for continuous time interaction93.  Examination of the nutrient density choline-CHD 
association in quartile models suggested a non-linear association; thus, nutrient density 
choline and total choline (betaine + choline) were examined in individual models as 
continuous variables with a quadratic term.  A directed acyclic graph (DAG) was 
constructed, based upon subject matter knowledge, to identify potential confounding 
relationships between covariates and the dietary choline-CHD relationship.94 We considered 
hypertension, physical activity, body size, dietary fat intake, type 2 diabetes, cigarette 
smoking, alcohol intake, and postmenopausal hormone therapy as possible confounders.  
Fully adjusted and backwards regression models were constructed.  A covariate was retained 
if its removal from the fully-adjusted model changed the parameter point estimate more than 
10%. 93, 95 We excluded participants with betaine, choline, dietary folate equivalents (DFE), 
B6, B12, or methionine values above the respective 99th percentiles from the analysis set. 
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However, we examined the effect of Winsorizing the upper end betaine, choline, B6, B12, 
folic acid, and methionine extreme values at the 99th percentile in the fully-adjusted models.  
 We corrected for measurement error of dietary methyl donor intake (choline, choline 
+ betaine, B6, B12, methionine, folate) using applied regression calibration.67, 96, 97 We 
estimated the within-person repeatability of the WHI FFQ estimates of the methyl donors in 
DM Usual Diet arm participants who completed a WHI FFQ at both enrollment and also at 
one-year follow-up (n=25,701).  The intra-individual variability was calculated and the 
correlation between measures made at repeat visits (reliability coefficient) was estimated 
using mixed models regression.98  The reliability coefficients used for calibration were 0.52 
for choline (0.52 for choline + betaine), 0.31 for folate, 0.51 for methionine, 0.60 for B6, 0.55 
for B12. We used a bootstrapping technique, sampling 1,000 times, to estimate the variance of 
beta coefficients obtained in the final longitudinal analysis corrected for measurement error.  
 Recognizing the metabolic relation between choline and betaine and the methyl-
exchange relation between choline and folate, 9, 99 we modeled each of these interactions in 
separate models.  Interaction p-values < 0.20 were considered significant.    
 
RESULTS  
The combined study size of the OS and DM included 142,511 postmenopausal 
women.  After excluding WHI participants who had missing dietary information for 
estimated baseline choline or betaine (n = 245), the women assigned to dietary intervention 
arm of the DM Dietary Modification Trial (n=19,470), and individuals who reported 
implausible daily caloric intake values (< 600 kcal/day n = 3,311 and > 5000 kcal/day n 
=303) there were 119,182 observations (29,173 DM and 90,009 OS).  From this set we 
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excluded participants with betaine, choline, DFE, B6, B12, or methionine values above the 
respective 99th percentiles (n=4,798).  As a result, these analyses were based on 114,384 
examinees (27,968 DM and 86,416 OS).   
The characteristics of the population are presented in Table IV.3.1 by quartile of 
nutrient density adjusted choline defined within the total population (n=114,384).  Black 
women were more frequently in the lowest quartile of choline intake quartile 1 (Q1): 34%. 
Younger participants more frequently had lower intakes of choline (White (Q1): 36%, Q4: 
27% and Black: Q1: 44%, Q4: 37%).  The prevalence of obesity (BMI ≥30) in White women 
was higher with increasing quartile of choline (Q1: 24%, Q4: 29%). The prevalence of 
hypertension in Black women was higher with increasing levels of choline intake (Q1: 19%, 
Q4: 24%). The prevalence of treated diabetes (White Q1: 2%, Q4: 5% and Black: Q1: 7%, 
Q4: 19%) and > 8 MET/week physical activity (White Q1: 50%, Q4: 57% and Black: Q1: 
36%, Q4: 43%) increased with choline intake. 
 Through the maximum 12 years of follow-up, the mean follow-up time was 10.2 
years.  Of the 96,065 White and 9,160 Black participants, 3,645 (3.8%) White women and 
333 (3.6%) Black women experienced an incident CHD event resulting in 3.69 and 3.90 
events per 1,000 person years, respectively.   The incidence of CHD increased with 
increasing quartile of choline (White Q1: 3.6, Q4: 4.2% and Black: Q1: 2.8%, Q4: 4.6%). 
Examination of the choline-CHD association in quartile models suggested non-
linearity of the association in Whites; therefore, choline and total choline (betaine + choline) 
were examined in individual models as continuous variables with a quadratic term (Table 
IV.3.2).  Ninety-three percent (93%) of White and 92% of Black women had complete data 
on all covariates. The fully adjusted hazard ratios (HR) of CHD (Table IV.3.2, Model 1) 
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associated with a one standard deviation (SD) increase of nutrient density adjusted choline 
intake (35.30 mg/dy per kilocarlorie) for Black women was 1.26 [95% confidence interval 
(CI): 1.09,1.46].  The HR for CHD in White women was 1.06 (95% CI: 1.01, 1.11).  
Estimates were similar when not adjusted for body size and alcohol intake (Table IV.3.2, 
Model 3).  
 
Winsorizing the upper end betaine, choline, B6, B12, DFE, and methionine extreme 
values at the 99th percentile, instead of assigning those observations a missing value, results 
in a change of a sample size from 114384 to a Winsorized sample size of 119182. The largest 
difference between HRs for the dataset with restricted/ truncated extreme values and 
Winsorized was 0.03 in the Black choline and choline plus betaine HRs (Table IV.3.3).  The 
95% CI for the choline model for Black women did not include the null (1.07, 1.41). When 
vitamin B6, vitamin B12, and folic acid supplement use are entered into the model, the HRs in 
the Winsorized models are identical.  
After the correction for measurement error of the B vitamins intakes was applied, the 
HRs ratios for Black women moved further from the null [HR one SD:  1.42 (95% CI: 1.03, 
1.86)]. Similar effects of measurement error adjustment were observed for White women 
[HR one SD:  1.13 (95% CI: 1.02, 1.23). 
When nutrient density adjusted total choline intake was considered, no association 
with incident CHD was observed.  To better characterize the attenuation of the effect 
estimate observed after the addition of betaine, referred to as the total choline (betaine + 
choline) model, we examined the interactions in the association of betaine and choline intake 
with incident CHD. Betaine and choline were included as separate variables and an 
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interaction term between the two was added within a measurement error correct, full-adjusted 
model.  The interaction terms were not statistically significant (p > 0.2) the models for White 
or Black women.    
Given the methyl-exchange relation between choline and folate, we also assessed 
possible interactions between total folate and choline intake in the association with incident 
CHD.  The interaction term was not statistically significant (p > 0.2) in the models for the 
White or Black women.   
 
DISCUSSION 
We observed a strong association between choline intake adjusted for measurement 
error and the hazard of incident CHD Black women [HR one SD:  1.26 (95% CI: 1.09,1.46)] 
and a more modest association in White women  [HR one SD:  1.06 (95% CI: 1.01, 1.11)].  
This effect was consistent across levels of betaine and folate intake within the proportional 
hazard model with no evidence of effect measure modification.  
This large (n=114,384), prospective cohort study of women ages 50-79 years 
examined the relation of choline intake estimated from the 122-item WHI FFQ with incident 
CHD while considering intra-individual one-year variability in micronutrient methyl donor 
intake.  To our knowledge this is this first study to examine associations between 
micronutrient methyl donor intake and incident CHD by race, nutrient density choline was 
found to be associated with incident CHD in White and in Black women, with a substantially 
greater effect in Blacks.  Correction for reliability increased the magnitude of the effect 
estimate associated with a one SD greater nutrient density choline by 7% in White women 
(1.06 versus 1.13) and 13% in Black women (1.26 versus 1.42).   
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White women comprised 84% (96,065 /114,384) of the total population, which was 
used to define the quartiles of dietary intake of choline. A substantial proportion of Black 
women had intakes of choline in the lowest quartile (34%).  
Ours is the second study to assess the association between choline intake and incident 
CHD while accounting for the reliability of the dietary assessment, the first being Bidulescu 
et al. 2007.8  In the ARIC population, neither higher intakes of dietary choline nor choline 
plus betaine were significantly associated with incident CHD over an average of 14 years of 
follow-up .18 Compared with the lowest quartile of intake, the risk of incident CHD was 
higher [HR = 1.09 (95% CI: 0.79, 1.50)] and [HR =1.14 (95% CI: 0.83, 1.56)] in the highest 
quartile of choline and choline +betaine, respectively.  Over an average 8 years of follow-up 
in PROSPECT–EPIC, the highest quartile of choline had a higher risk of incident CHD 1.28 
(95% CI: 0.86, 1.91) compared to the lowest.17 Effect estimates from PROSPECT–EPIC, 
comparing Q1 (referent) to Q4, was similar to the HR we observed for Black women, and the 
ARIC results aligned with our findings for White women.  However the 95% CI for these 
estimates included the null in each of the previous studies. In our study, the 95% CIs were 
more precise compared to previous studies and did not contain the null.  
Exposure measurement error can bias estimated measures of association, and result in 
underestimation of their variance and affect the power of statistical tests for association81, 82 
83, which motivated us to fit Cox proportional hazard models accounting for the reliability of 
the dietary assessment. Correction for the reliability of the B vitamins intakes resulted in HRs 
for choline further from the null in Black [HR one SD: 1.42 (95% CI: 1.03, 1.86) and in 
White women [HR one SD: 1.13 (95% CI: 1.02, 1.23)].  A similar movement away from the 
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null was observed for the total choline models, although the confidence intervals about the 
estimates still contained the null.   
Bidulescu et al. 2007 corrected effect estimates for choline and total choline using 
assessments of reliability from a random sample of 1,004 subjects whose dietary intake was 
measured three years after the ARIC baseline 8. Comparing quartile 1 (referent) to quartile 4, 
HRs for choline were 1.09 (0.74, 1.59) and 1.50 (1.00, 2.26) for choline plus betaine. This 
adjustment revealed that measurement error in the ARIC study resulted in attenuation of the 
estimated HR for total choline, and no change in the estimated effect for choline alone.  We 
found that measurement error resulted in attenuation of both associations with a greater bias 
occurring for the total choline estimate. 
Similar to Bidulescu et al. 8 we examined total choline as the sum of choline and 
betaine. This combined variable resulted in an attenuated effect estimate for total choline 
[1.07 (95% CI: 0.94, 1.22) and 1.03 (95% CI: 0.98, 1.07) in Black and White women, 
respectively.  Recognizing the metabolic relation between choline and betaine and the 
methyl-exchange relation between choline and folate, 9, 99 we estimated each of these 
interactions in separate models.  Betaine and choline intake were also modeled as individual 
variables with interaction terms, the effect estimates for the relation of betaine with incident 
CHD was about the null and there was no evidence in support of interaction on the 
multiplicative scale (p > 0.2). 
Dietary choline demand is modified by the metabolic methyl-exchange relationships 
between choline and three nutrients: methionine, folate, and B12.9, 99.Since there is methyl-
exchange relation between choline and folate, we also assessed a plausible interaction of 
choline and folate intakes.   The interaction term between total folate and choline intake in 
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the association with incident CHD was not statistically significant (p > 0.2) in either the 
White or the Black women.   
Phosphatidylcholine is necessary for the synthesis of very low-density lipoprotein-
cholesterol (VLDL) particles. Individuals with choline deficiency have lower plasma low-
density lipoprotein-cholesterol (LDL)1 and tend to accumulate fat and cholesterol in the liver. 
Betaine supplementation in turn has been related to increases in LDL.2-4 Increased whole 
blood levels of total choline have previously been found to be associated with cardiovascular 
disease.5, 6 While it is not clear whether this association of betaine with lipid concentrations 
results in a clinically meaningful effect,100 our study suggests that the association of total 
choline with incident CHD is consistent across varying intakes of betaine and folate.   
A limitation in the design of our study is that habitual choline and total choline were 
estimated using a food frequency questionnaire, the WHI FFQ, which can underestimate the 
absolute dietary intake. Objective biomarkers have been successfully used in WHI to 
calibrate self-reports, but biomarkers were not available for the nutrients addressed in this 
report. A further limitation applies to the FFQ repeatability analysis, derived from the  one-
year long interval between FFQ assessments, which may have incorporated some meaningful 
changes in dietary intake over this time period. This may have contributed to the modest 
level of repeatability we observed and effected the reliability correction.  However, the 
period across which reliability was assessed is substantially shorter than in other studies, such 
as Bidulescu et al. 200718, that used FFQs administered three years apart. 
In conclusion, increased nutrient density choline intake was associated with incident 
CHD in White and Black women, with a substantially greater effect estimate in the latter. 
This relation was not modified by betaine or folate intake. Correction for reliability 
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demonstrated that measurement error results in substantial attenuation of effect estimates. 
The findings from this third such study of choline and incident CHD provides further 
evidence in support of a positive association.  The possible differential effect by race/ 
ethnicity requires further evaluation and replication. 
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Table IV.3.1 Characteristics of the 96,065 White and 9,160 Black participants in the Women's Health Initiative across quartiles 
of Women’s Health Initiative Food Frequency Questionnaire estimate of nutrient density dietary choline intake at enrollment. 
 
  Quartile of Dietary Choline per Kilocalorie 
 Whites (n = 96,065)  Blacks (n = 9,160) 
Characteristic Quartile 1 Quartile 2 Quartile 3 Quartile 4  Quartile 1 Quartile 2 Quartile 3 Quartile 4 
 (n=22,879) (n=24,106) (n=24,665) (n=24,415)  (n=3,114) (n=2,190) (n=1,831) (n=2,025) 
Choline <149.89 mg/d 
149.90 
-170.08 
mg/d 
170.09 
-192.83 mg/d >192.84 mg/d 
 
<149.89 
mg/d 
149.90 
-170.08 
mg/d 
170.09 
-192.83 
mg/d 
>192.84 
mg/d 
          
Incident CHD          
   No 22053 (96.4) 
23264 
(96.5) 23716 (96.2) 23387 (95.8)  3028 (97.2) 2114 (96.5) 1754 (95.8) 1931 (95.4) 
   Yes 826 (3.6) 842 (3.5) 949 (3.9) 1028 (4.2)  86 (2.8) 76 (3.5) 77 (4.2) 94 (4.6) 
          
Age at screening, y          
   50-59 8203 (35.9) 7959 (33.0) 7506 (30.4) 6514 (26.7)  1381 (44.4) 911 (41.6) 689 (37.6) 747 (36.9) 
   60-69 9803 (42.9) 
10760 
(44.6) 11326 (45.9) 11447 (46.9)  1292 (41.5) 941 (43.0) 800 (43.7) 920 (45.4) 
   70-79 4873 (21.3) 5387 (22.4) 5833 (23.7) 6454 (26.4)  441 (14.2) 338 (15.4) 342 (18.7) 358 (17.7) 
          
Smoking, n (%)          
    Never 11042 (48.9) 
11954 
(50.2) 12346 (50.6) 12007 (49.8)  1482 (48.5) 1072 (50.1) 916 (51.1) 950 (48.0) 
    Past 10086 (44.7) 
10525 
(44.2) 10726 (44.0) 10574 (43.9)  1224 (40.1) 856 (40.0) 693 (38.7) 813 (41.1) 
    Current 1463 (6.5) 1332 (5.6) 1321 (5.4) 1522 (6.3)  350 (11.5) 213 (10.0) 182 (10.2) 217 (11.0) 
          
Body mass index, kg/m2          
     <25 9680 (42.7) 9878 (41.4) 9451(38.7) 8597 (35.6)  614 (19.9) 345 (15.9) 306 (16.9) 282 (14.1) 
     25-<30 7492 (33.0) 8257 (34.6) 8603 (35.3) 8639 (35.8)  1023 (33.2) 735 (33.8) 638 (35.2) 635 (31.6) 
     ≥30 5518 (24.3) 5748 (24.1) 6346 (26.0) 6912 (28.6)  1446 (46.9) 1093 (50.3) 867 (47.9) 1090 (54.3) 
          
Alcohol use, n  (%)          
  Nondrinker 2121 (9.3) 1960 (8.2) 2013 (8.2) 2134 (8.8)  519 (16.8) 351 (16.3) 287 (15.9) 361 (18.1) 
  Past drinker 3853 (16.9) 3695 (15.4) 3826 (15.6) 4409 (18.2)  1040 (33.7) 732 (33.9) 572 (31.7) 676 (33.9) 
   <1 drink per month 2835 (12.5) 2607 (10.9) 2785 (11.3) 3049 (12.6)  441 (14.3) 268 (12.4) 242 (13.4) 248 (12.4) 
  
15 150 
   <1 drink per week 4388 (19.3) 4921 (20.5) 5292 (21.6) 5411 (22.3)  526 (17.1) 401 (18.6) 353 (19.6) 357 (17.9) 
   1-<7 drinks per week 5765 (25.3) 7146 (29.8) 7474 (30.4) 6915 (28.5)  410 (13.3) 302 (14.0) 271 (15.0) 281 (14.1) 
   > 7 drinks per week 3810 (16.7) 3676 (15.3) 3160 (12.9) 2372 (9.8)  148 (4.8) 104 (4.8) 81 (4.5) 73 (3.7) 
          
Prevalence of hypertension, n 
(%)           
   Normotensive 13603 (59.8) 
14255 
(59.5) 14347 (58.5) 13778 (56.8)  1141 (36.9) 785 (36.1) 611 (33.6) 646 (32.4) 
   Unconfirmed Hypertensive 1008 (4.4) 1019 (4.3) 1096 (4.5) 1095 (4.5)  161 (5.2) 124 (5.7) 79 (4.3) 106 (5.3) 
   Hypertensive 8147 (35.8) 8691 (36.3) 9083 (37.1) 9381 (38.7)  1789 (57.9) 1261 (58.1) 1131 (62.2) 1245 (62.3) 
      Self-report, confirmed     
with medication 2858 (12.6) 3156 (13.2) 3448 (14.1) 3547 (14.6)  752 (24.3) 534 (24.6) 491 (27.0) 493 (24.7) 
         Elevated BP 3236 (14.2) 3241 (13.5) 3209 (13.1) 3314 (13.7)  450 (14.6) 300 (13.8) 245 (13.5) 280 (14.0) 
            Both 2053 (9.0) 2294 (9.6) 2426 (9.9) 2520 (10.4)  587 (19.0) 427 (19.7) 395 (21.7) 472 (23.6) 
          
Diabetes treated (pills or 
injections), n (%)          
   No 22451 (98.2) 
23486 
(97.5) 23830 (96.7) 23247 (95.3)  2881 (92.7) 1965 (89.9) 1587 (86.8) 1634 (80.8) 
   Yes 415 (1.8) 605 (2.5) 815 (3.3) 1144 (4.7)  228 (7.3) 221 (10.1) 241 (13.2) 388 (19.2) 
          
Percent energy from fat 0.34 (0.085) 
0.32 
(0.081) 0.31 (0.081) 0.30 (0.085)  
0.35 
(0.084) 
0.34 
(0.080) 
0.34 
(0.083) 
0.33 
(0.089) 
          
Hormone use, n (%)          
   Never 8873 (38.8) 9023 (37.5) 9395 (38.1) 9655 (39.6)  1865 (60.0) 1205 (55.2) 1042 (56.9) 1186 (58.6) 
   Past  3285 (14.4) 3638 (15.1) 3655 (14.8) 3776 (15.5)  409 (13.2) 333 (15.3) 258 (14.1) 276 (13.6) 
   Current 10707 (46.8) 
11426 
(47.4) 11598 (47.1) 10957 (44.9)  833 (26.8) 645 (29.6) 530 (29.0) 562 (27.8) 
          
Physical activity, MET/week, 
n (%)          
   None 3753 (17.1) 3020 (13.0) 3035 (12.7) 2946 (12.4)  769 (25.5) 462 (21.7) 368 (20.6) 403 (20.5) 
   >0-3.5 3121 (14.2) 3113 (13.4) 3020 (12.7) 3061 (12.9)  596 (19.7) 403 (18.9) 314 (17.6) 344 (17.5) 
   >3.5-8.0 4034 (18.4) 4229 (18.2) 4378 (18.4) 4177 (17.6)  554 (18.4) 422 (19.8) 350 (19.6) 368 (18.7) 
   >8.0-16.5 4795 (21.9) 5716 (24.6) 5847 (24.5) 5681 (23.9)  559 (18.5) 407 (19.1) 367 (20.5) 371 (18.8) 
   >16.5 6207 (28.3) 7147 (30.8) 7548 (31.7) 7904 (33.3)  541 (17.9) 438 (20.5) 388 (21.7) 483 (24.5) 
           
  
15 151 
Missing: in Q1, Q2, Q3, Q4, (Total) 
Smoking status: White 288, 295, 272, 312 (1167) and Black 58 49 40 45 (192) 
BMI: White 189, 223, 265, 267 (944) and Black 31, 17, 20, 18 (86) 
Alcohol: White 107, 101, 115, 125 (448) and Black 30, 32, 25, 29 (116) 
Prevalence of hypertension: White 121, 141, 139, 161 (562) and Black 23, 20, 10, 28 (81) 
Diabetes treated (pills or injections): White 13, 15, 20, 24 (72) and Black 5, 4, 3, 3 (15) 
Hormone use: White 14, 19, 17, 27 (77) and Black 7, 7, 1, 1 (16)  
Physical activity, MET/week: White 969, 881, 837, 646 (3333) and Black 95, 58, 44, 56 (253) 
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Table IV.3.2 Cox proportional hazard estimates (and 95% confidence intervals) for incident 
coronary heart disease through 12 years of follow-up in White (n = 89,741) and Black 
(n=8,389) Women's Health Initiative (WHI) participants. 
 Whites (n = 89,741)  Blacks (n = 8,389) 
 
Hazard 
Ratio 
95% 
confidence 
interval  
Hazard 
Ratio 
95% 
confidence 
interval 
      
One Standard Deviation Increase in Nutrient Density Choline 
Model 1 Full Adjusted* 1.06 (1.01, 1.11)  1.26 (1.09,1.46) 
                                     
Model 2 Full Adjusted Reliability 
Correction* 1.13 (1.02, 1.23)  1.43 (1.03, 1.86) 
                                     
Model 3 Minimal Adjusted† 1.06 (1.01, 1.11)  1.26 (1.09, 1.45) 
                                     
Model 4 Minimal Adjusted 
Reliability Correction† 1.13 (1.02, 1.25)  1.42 (1.03 1.84) 
                                     
One Standard Deviation Increase Nutrient Density Choline + Betaine 
Model 1 Full Adjusted* 1.01 (0.97, 1.06)  1.07 (0.94, 1.21) 
      
Model 2 Full Adjusted Reliability 
Correction* 1.02 (0.93, 1.13)  1.05 (0.83, 1.37) 
                                     
Model 3 Minimal Adjusted† 1.03 (0.98, 1.07)  1.07 (0.94, 1.22) 
      
Model 4 Minimal Adjusted 
Reliability Correction† 1.07 (0.74, 1.26)  1.09 (0.84, 1.36) 
      
 
* Adjusted for hypertension, physical activity, body size, percent energy from fat, type 2 diabetes, 
cigarette smoking, alcohol intake, postmenopausal hormone therapy, and nutrient density scaled: B6; 
B12; methionine; total folate  
† Adjusted for hypertension, physical activity, percent energy from fat, type 2 diabetes, cigarette 
smoking, postmenopausal hormone therapy, and nutrient density scaled: B6; B12; methionine; total 
folate 
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Table IV.3.3 Cox proportional hazard estimates (and 95% confidence intervals) for incident 
coronary heart disease through 12 years of follow-up comparing truncated to winsorized 
values at 99th percentile for betaine; choline; B6,; B12; folic acid; methionine dietary intake 
 
N 
Hazard 
Ratio 
95% Confidence 
Intervals 
One SD Increase in Nutrient Density Choline 
WHITE CHOLINE 
    Truncated* 89,741 1.06 1.01 1.11 
Winsorized* 93,084 1.06 1.01 1.11 
Winsorized (Supplement Use Yes/ No) *† 93,084 1.06 1.01 1.11 
     
BLACK CHOLINE 
    Truncated* 8,389 1.26 1.09 1.46 
Winsorized* 9,050 1.23 1.07 1.41 
Winsorized (Supplement Use Yes/ No) *† 9,050 1.23 1.07 1.41 
     
One SD Increase in Nutrient Density Choline + Betaine 
WHITE CHOLINE + BETAINE 
    Truncated* 89,741 1.01 0.97 1.06 
Winsorized* 93,084 1.02 0.98 1.06 
Winsorized (Supplement Use Yes/ No) *† 93,084 1.02 0.98 1.06 
     
BLACK CHOLINE + BETAINE 
    Truncated* 8,389 1.07 0.94 1.21 
Winsorized* 9,050 1.04 0.92 1.17 
Winsorized (Supplement Use Yes/ No) *† 9,050 1.04 0.92 1.17 
 
* Adjusted for hypertension, physical activity, body size, percent energy from fat, type 2 diabetes, 
cigarette smoking, alcohol intake, postmenopausal hormone therapy, and nutrient density scaled: B6; 
† Also adjusted for B6, B12, and folic acid supplement use 
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CHAPTER V  
CONCLUSIONS 
V.1 Summary of Findings 
This doctoral research estimated the dietary intake of choline and betaine in the 
Women’s Health Initiative (WHI).  It also ascertained the variability in the WHI Food 
Frequency Questionnaire (FFQ) with reference to a four-day food record (FDFR) and 
ascertained the intra-individual one-year variability in WHI FFQ measurements of estimated 
intakes of betaine, choline, folate, methionine, B6 and B12.  Based on the former, we 
estimated the association corrected for reliability between habitual intake of choline and 
betaine and incident coronary heart disease in the WHI. 
In this first study among postmenopausal women (50-79 years of age), the dietary 
intake of choline and betaine estimated from a 122 item FFQ, supplemented with ethnic food 
items, is similar to that reported by previous, more homogeneous studies in different locales. 
Due to the WHI’s large sample size and emphasis on inclusion of racial/ethnic groups1, we 
were able to characterize betaine and choline intake among women in racial/ethnic sub-
groups. Notably lower betaine and choline intake was observed for Hispanic/Latinos and 
Asian or Pacific Islanders.  Since food items were added to the WHI FFQ to incorporate 
regional and ethnic foods in the United States,2, 3 the observed patterns could be attributable 
to actual differences in consumption or alack of ethnic foods containing 
 164 
betaine and choline.  There was only modest variability in the dietary intake of betaine and 
choline by U.S. geographic region.   Although seasonal variability in the intake of choline 
and betaine was detected, the magnitude of these variations is small. The estimated 
population dietary choline values we found are lower than the 1998 Adequate Intake 
established by the Food and Nutrition Board of the Institute of Medicine of the National 
Academy of Sciences.  
When examining dietary variability in the WHI FFQ, with reference to a FDFR and 
intra-individual one-year variability in WHI FFQ, we used the following benchmarks: slight 
reliability, r = 0.00-0.20; fair reliability, r = 0.21-0.40; moderate reliability, r = 0.41-0.60; 
substantial reliability, r = 0.61-0.80; almost perfect reliability, r = 0.81-1.004. The baseline 
and one-year FFQ estimates for the micronutrients showed moderate agreement, with the 
exception of DFE. In contrast, micronutrients estimated from FDFR and FFQs were only 
slightly-to-fairly correlated. Exposure measurement error can bias measures of association 
and result in underestimation of their variance, affecting the power of statistical tests for 
association.4, 5 6  The moderate reliability of the FFQ observed for most micronutrients when 
administered one year apart suggested that variability should be considered when estimating 
intake levels of these micronutrients, as well as their associations with health outcomes.  We 
therefore accounted for the reliability of the dietary assessment when examining which 
associations with incident CHD using Cox proportional hazard models.  
Based on the hypothesis that dietary betaine and choline intake may be associated 
with CHD and through the homocysteine methylation pathway we examined the relation 
between B vitamins and incident CHD events.  This was indicated by studies that showed 
dietary betaine and choline may be important for lowering plasma homocysteine 
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concentrations through methylation of homocysteine to form methionine, even when dietary 
consumption of folate and other B vitamins is adequate.  Contrary to expectations the 
findings from our study indicated a positive (direct) association between choline intake and 
incident CHD. 
Over the course of a mean follow-up time was 10.2 years (maximum 12 years of 
follow-up) the fully adjusted hazard ratios (HR) of the risk of CHD associated with a one 
standard deviation (SD) greater nutrient density adjusted choline intake (35.30 mg/dy per 
kcal) for Black women was 1.26 [95% confidence interval (CI): 1.09,1.46] and in White 
women was 1.06 (95% CI: 1.01, 1.11). After the correction for error in the measurement of 
the B vitamin intakes was applied, the associations strengthened for Black women moved 
further from the null [HR one SD:  1.42 (95% CI: 1.03, 1.86)] and White women [HR one 
SD:  1.13 (95% CI: 1.02, 1.23). We observed a similar strengthening of associations for the 
total choline models, although the confidence intervals about the estimates still contained the 
null.   
To place our findings in context, Bidulescu et al. 2007 corrected effect estimates for 
choline and total choline using assessments of reliability from a random sample of 1,004 
subjects whose dietary intake was measured three years after their baseline measurement in 
the ARIC study.7  Comparing the lowest quartile of intake (referent) to the highest quartile, 
estimated HRs for choline were 1.09 (0.74, 1.50) and 1.14 (0.83, 1.56) for choline plus 
betaine. Over an average 8 years of follow-up in PROSPECT–EPIC, the highest quartile of 
choline intake had a higher risk of incident CHD 1.28 (95% CI: 0.86, 1.91) compared to the 
lowest.8 Effect estimates from PROSPECT–EPIC, comparing Q1 (referent) to Q4, were 
similar to the HR we observed for Black women, and the ARIC results aligned with our 
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findings for White women.  However the 95% CI for these estimates included the null in 
each of the previous studies. In our study, the 95% CIs were more precise compared to 
previous studies and did not contain the null.  
Recognizing that there is a metabolic relation between choline and betaine and the 
methyl-exchange relation between choline and folate,9, 10 we estimated each of these 
interactions in separate models.  We found no evidence of modification on the multiplicative 
scale (p > 0.2) of the association of betaine with incident CHD.  Dietary choline demand is 
modified by the metabolic methyl-exchange relationships between choline and three 
nutrients: methionine, folate, and B12.9, 10 Given the methyl-exchange relation between 
choline and folate, we also assessed a plausible interaction of choline and folate intakes but 
found no modification between total folate and choline intake in the association with incident 
CHD (p > 0.2) in either White or Black women.   
The findings from this study provide further evidence in support of a positive 
association of choline and incident CHD. The differential strength of this association 
observed by race requires further evaluation and replication. These observed associations are 
biologically plausible. Phosphatidylcholine is necessary for the synthesis of very low-density 
lipoprotein-cholesterol (VLDL) particles. Individuals with choline deficiency have lower 
plasma low-density lipoprotein-cholesterol (LDL)11 and tend to accumulate fat and 
cholesterol in the liver. Betaine supplementation in turn has been related to increases in LDL 
12-14 and increased whole blood levels of total choline have previously been found to be 
associated with cardiovascular disease.15, 16  While it is not clear whether this association of 
betaine with lipid concentrations results in a clinically meaningful effect,17  our study 
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suggests that the association of choline with incident CHD is consistent across varying levels 
of intake of betaine and folate.   
 
V.2 Strengths and Limitations 
Only four studies have examined the relationship between these outcomes and 
habitual dietary choline and betaine. In addressing this deficiency this study was able to draw 
on the large and well-characterized OS (n=93,676) and the DM trial (n=48,835) of the WHI 
Study.  Both of these studies have extensive follow-up periods (Mean follow-ups: 90.9 OS 
and 97 months DM) and high retention rates. The postmenopausal women in these studies 
ranged in age from 50 to 79 years at time of enrollment and represent a population at 
significant risk for CHD. Additional strengths of this study were the ability to examine the 
temporality of relations between dietary choline intake and incident CHD, the reliance on 
carefully standardized, validated exposure estimation and the ability to correct for 
measurement error.   
Like previous large cohort studies, a limitation of this study is that the choline and 
betaine intake were estimated using a semi-quantitative dietary assessment tool, a FFQ, to 
asses dietary intake which tends to underestimate the absolute dietary intake for a particular 
nutrient.  Furthermore, nutrient intakes cannot be directly compared between studies which 
utilize different FFQs.  All four previous studies, as well as ours, report population dietary 
choline values substantially lower than the AI.  Fischer et al 18 demonstrated that there are 
differences between actual choline intake and those estimated from food records where 
reported choline intakes are considerably lower.  However, the proportion of choline intake 
as a fraction of total energy intake is similar for actual and reported diet.  These differences 
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were attributed to underreporting of energy intake for food records.16  Objective biomarkers 
have been successfully used in WHI to calibrate self-reports, but biomarkers were not 
available for the nutrients addressed in this report.  
A further limitation applies to the FFQ repeatability analysis, derived from repeated 
FFQ measurements with a one-year long interval between FFQ assessments, Differences 
across the year may have incorporated some meaningful changes in dietary intake over this 
time period in addition to measurement error, which could have contributed to the modest 
level of repeatability we observed and effected the reliability correction.  However, the 
period across which reliability was assessed is substantially shorter than in other studies, such 
as Bidulescu et al. 2007,19 that used FFQs administered three years apart. 
The food records used to compare FDFRs to FFQs came from DM participants who 
over the course of follow-up developed breast cancer, colorectal cancer, ovarian cancer, or 
coronary heart disease cases. All FDFRs and FFQs from this case-only subset were 
completed prior to case diagnosis; while it is possible that subclinical disease could have 
affected the participants’ diets in advance of manifest morbidity, it is less likely that it would 
have influenced the way in which an individual completes both the FFQ and FDFR. 
Therefore, it is unlikely that case status affected the observed relation between the FFQ and 
FDFR.  Intra-individual variation could not be estimated for the FDFR as only baseline 
assessments were available. 
 
V.3 Conclusions 
This large (n=114,384), prospective cohort study among women ages 50-79 years 
examined the relation of choline intake estimated from the 122-item WHI FFQ with incident 
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CHD while considering micronutrient methyl donor intra-individual one-year variability. 
Choline was found to be associated with incident CHD in Whites and Blacks with a 
substantially greater effect within Blacks.  Correction for reliability of the FFQ estimates 
demonstrated that measurement error would result in substantial attenuation of effect 
estimates. Correction for reliability increased the strength of association with a one SD 
difference of nutrient density choline by 7% in Whites (1.06 versus 1.13) and 13% in Blacks 
(1.26 versus 1.42).    
Increased nutrient density choline intake was associated with incident CHD in Whites 
and Blacks with a substantially greater effect estimate within Blacks.  The possible 
differential effect by race/ ethnicity requires further evaluation and replication. The findings 
from this third such study of choline and incident CHD provides further evidence in support 
of a positive association; however, no study has examined the proportional reduction in 
incident CHD that would occur by modifying choline exposure.  Because our study examined 
choline as calculated by NDSR that grouped free choline and esterified forms 
(phosphocholine, glycerophosphocholine, phosphatidylcholine, and sphingomyelin) into one 
choline exposure variable, future studies should assess whether the association of choline and 
incident CHD varies by the form of dietary choline. 
We further submit that future work should examine the attributable disease burden 
associated with increased intake of choline. The population-attributable risk estimates should 
be based on plausible levels of intake and not presume complete elimination of a choline 
intake.  While choline can be biosynthesized de novo, the concentration of free choline in 
serum and tissues is heavily dependent on the dietary intake of choline,20-27 as humans can 
become depleted of choline and betaine.28, 29  Choline depletion can affect health status, as it 
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is a micronutrient that is essential for normal function of all cells9. Choline directly affects 
cholinergic neurotransmission 21, 30-32, and directly affects lipid transport from the liver. 9, 33-35  
Correspondingly, the attributable disease burden should be assessed using estimates of 
choline intake based on realistic and attainable lowering of the population distribution, using 
metrics such as a Potential Impact Fraction (PIF).36, 37     
Since we only examined the relations between choline intake and a single 
cardiovascular disease manifestation, the relation of choline intake should be further 
investigated with other atherothrombotic endpoints such as ischemic stroke.  Importantly, 
dietary choline and betaine deficiencies decrease S-adenosylmethionine (SAMe) 
concentrations which results in DNA hypomethylation 38, 39 which may result in increased 
expression of oncogenes and an increased risk of DNA mutations, thus providing a basis for 
primary tumor growth and metastasis.  Associations between DNA hypomethylation and 
colorectal,40 breast,41 and lung cancer 42, 43 have been reported. Thus, similar investigations 
may be warranted for the relation between choline and colorectal, breast, and lung cancers. 
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